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Abstract 
 
Biomarkers of Atherosclerosis 
A study of plasma and solid tissues from animal and human models using 
nuclear magnetic resonance (NMR) technology 
By Peshang Abdulhannan 
Submitted for the degree of M.D., January 2018 
 
Introduction: Current recommendations for surgical management of 
asymptomatic 50-99% carotid stenosis are guided by two factors, patient’s fitness 
for surgical intervention and the clinical/imaging features associated with an 
increased risk of late stroke. Despite the advances in imaging modalities and their 
ability to detect some features of plaque instability, full understanding the 
pathophysiology of plaque instability will allow early intervention in patients with 
high risk of developing stroke from the unstable plaque. To date, no serum or 
urine marker has been shown to predict plaque instability and the risk of future 
cerebrovascular events. 
 
Aims and methods: The aim of this study was to compare metabolic profiles of 
plasma and plaques from patients with symptomatic carotid stenosis undergoing 
endarterectomy, plasma and plaques from patients with symptomatic femoral 
stenosis, and plasma from patients without carotid or femoral disease (control). 
We also aim to compare plasma and solid tissues from mammalian model (mice), 
and further compare them to the human experiment. Nuclear magnetic 
resonance (NMR) spectroscopy will be used to analyse the metabolic profiles of 
plasma and plaques, and potentially identify predictive biomarkers of plaque 
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instability. Animal experiment was carried out using 6 apolipoprotein E–deficient 
versus 6 control mice. For the human experiment, carotid and femoral plaques 
alongside plasma and urine samples were collected from 84 patients. NMR 
analysis was performed on all the samples and further analysis was done on the 
resulting spectra and correlating data. 
 
Results: The animal experiment showed weak models with inconclusive 
outcomes. Plasma human experiment also showed weak models and could not 
confidently establish certain metabolites as atherosclerotic biomarkers. However, 
similarities were observed between the animal and human models, and 3 
metabolites (2-oxoglutarate, choline and taurine) were identified as potential 
biomarkers. In contrary, human solid tissue experiments have shown much 
stronger models and clearer results. Spectra gained from these experiments 
were the first to be described, with no comparable studies in the literature. The 
most notable finding is the possible effect of taurine on carotid plaques. Taurine 
signals have been observed in the animal (plasma and solid) as well as human 
plasma models in this study. Although, they were merely affecting the control 
groups.  
 
Conclusions: Identifying plaque instability in asymptomatic carotid disease was 
the centre of this study. Taurine’s strong influence on the metabolic profiling of 
carotid plaques raises the possibility of a potential biomarker of plaque instability. 
Further work is required regarding the histological examination of plaque 
sections. An objective assessment of the plaque instability will improve the study 
outcome and add a different aspect to the current results. 
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Chapter 1: Introduction and background 
 
Atherosclerosis is a systemic chronic inflammatory response to fatty deposition 
on the intima, resulting in thickening of the arterial wall and the formation of 
plaques. Atherosclerosis can affect the heart causing myocardial infarction, the 
brain causing stroke and the legs causing ischaemia which might lead to 
amputation. It is considered the main cause of death globally and counts for 
almost 50% of all deaths in western countries (Hansson, 2005) (Lusis, 2000) 
Stroke is one of the most common causes of death worldwide (Mathers, et al., 
2009) with carotid artery disease implicated in about 15% of ischaemic strokes  
(Naylor, et al., 2017). 
 
Acute events associated with carotid atherosclerosis are caused by plaque 
rupture and the creation of thrombus. Although changes in plaque morphology 
precede symptoms, understanding of the underlying pathophysiology is still 
inadequate. Therefore, identifying early biomarkers of plaque instability could 
potentially avoid these acute events and reduce morbidity and mortality rates 
related to them.  
 
The aim of this study is to identify biomarkers of carotid plaque instability using 
Nuclear Magnetic Resonance (NMR) spectroscopy, to be able to identify patients 
with unstable asymptomatic carotid disease. 
 
This chapter describes carotid and femoral atherosclerosis, risks factors and 
treatment methods. An explanation of plaque morphology and pathophysiology 
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is followed by an insight into omics technology and principles of metabolomic 
profiling using NMR and current advances in solid status NMR studies. 
 
1.1 Carotid Atherosclerosis 
Carotid atherosclerosis mainly affects the bifurcation of the common carotid 
artery and is a combination of focal accumulation of lipid in the intima (atheroma) 
and thickening of the media (atherosclerosis). Stroke related to carotid artery 
disease happens mainly due to plaque disruption and distal embolisation 
(Barnett, et al., 2000). 
 
1.1.1 Risk factors 
Risk factors for carotid artery disease (CAD) are similar to those for any 
atherosclerotic disease. These include non-modifiable factors (Age, sex and 
family history) and modifiable ones (smoking, hypertension, diabetes mellitus and 
dyslipidaemia). 
 
1.1.1.1 Age and sex 
Several studies have clearly indicated an increased risk of atherosclerosis with 
increasing age in both men and women (Newman, et al., 1999). Carotid disease 
incidence in under 50-year-olds is negligible (Kroger, et al., 1999) and rises above 
80% in over 90-year-olds (Homma, et al., 2001). The evidence of a gender 
difference is slightly less clear with some studies suggesting that men are at a 
higher risk of developing atherosclerotic plaques (Moody, et al., 1990) (Li, et al., 
1994). 
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1.1.1.2 Family history 
There have been a few studies emphasising the importance of family history of 
atherosclerosis on the presence of carotid artery disease (CAD). A recent cohort 
study of 864 patients with CAD compared to 1698 controls concluded that family 
history of stroke and of coronary artery disease were each associated with carotid 
artery disease, suggesting shared genetic and environmental factors contributing 
to its risk. The study also suggested that sibling history gives greater risk than 
parental history  (Khaleghi, et al., 2014). 
 
1.1.1.3 Smoking 
The relation between smoking and the prevalence of CAD is well established 
(Tell, et al., 1994). In fact, smoking is the single most important risk factor for 
atherosclerosis (Doll, et al., 2004). Analysing results from 4 large population-
based cohort studies suggested that smoking was associated with a significant 
increase in the incidence of internal carotid artery stenosis, with an odds ratio of 
2.3 (95% CI 1.8 – 2.8) for >50% stenosis and of 3 (95% CI 2.1 – 4.4) for >70% 
stenosis (de Weerd, et al., 2014).  
 
Furthermore, both current and ex-smokers who suffer from chronic infections 
associated with smoking (such as chronic obstructive pulmonary disease COPD, 
chronic bronchitis, recurrent upper respiratory tract infection, chronic 
gastrointestinal infection and chronic skin infection and ulceration) have an 
increased risk of atherosclerosis with odds ratios of 3.3 and 3.4 respectively 
(Kiechl, et al., 2002). 
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1.1.1.4 Hypertension 
There is good evidence that hypertension is a powerful predictor of 
cardiovascular events (Lawes, et al., 2008) (Liu, et al., 2015).  A blood pressure 
above 160/95 mmHg increases the risk of atherosclerosis by 2.5-4 fold (Murabito, 
et al., 1997) with most studies considering systolic hypertension a significant 
factor in carotid plaque development and progression (Willeit & Kiechl, 1993) (Su, 
et al., 2001). 
 
1.1.1.5 Diabetes Mellitus 
Diabetes mellitus (DM) has been recognized as one of the main elements for the 
presence and progression of carotid artery disease. Carotid intima-media 
thickness (IMT) has been defined as a valuable tool for risk stratification in this 
population (Bosevski, 2014) (Chambless, et al., 2002). However, this is disputed 
in some studies which report that DM is associated with plaque progression but 
not IMT (Van de Meer, et al., 2003). 
 
In other studies, DM has been defined as an independent factor for the presence 
of high-grade carotid-artery stenosis in the general population (Göksan, et al., 
2001) with Type 2 diabetes a considerable risk factor for the progression of 
atherosclerosis and the increase of carotid IMT (Bosevski & Stojanovska, 2015). 
The Northern Manhattan Study suggested that diabetes doubles the risk of 
stroke. It also suggested that the duration of diabetes is independently linked to 
ischaemic stroke risk (Banerjee, et al., 2012). However, there is no clear evidence 
of its association with plaque instability (Scholtes, et al., 2014). 
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1.1.1.6 Dyslipidaemia 
The exact association between dyslipidaemia, carotid artery disease and stroke 
is yet to be fully understood with mixed epidemiological evidence relating 
cholesterol levels to the incidence and progression of atherosclerosis. Most 
evidence suggests that high low-density lipoprotein cholesterol (LDL-C) levels or 
low high-density lipoprotein cholesterol (HDL-C) are independent risk factors for 
carotid artery atherosclerosis (Fabris, et al., 1994) (Demarin, et al., 2010). The 
Framingham study linked total cholesterol levels with raised risk of carotid artery 
disease (O'Leary, et al., 1992b), while some recent studies have indicated that 
total triglyceride (TG) is an independent risk factor for carotid plaques (Mi, et al., 
2016). 
 
The use of lipid-lowering agents (such as statins) has shown a reduction in 10-
year stroke risk from 24.1% to 13.4% in patients who were treated conservatively, 
and from 17.9% to 7.6% in patients who were treated with carotid endarterectomy 
(Halliday, et al., 2010). A Cochrane review of 18 randomised controlled trials on 
statins role in preventing cardiovascular disease, showed a significant reduction 
in stroke rate in patients on statins compared to the control group (Relative risk 
0.78, 95% CI 0.68 – 0.89) (Taylor, et al., 2013). 
 
1.1.2 Clinical symptoms of carotid artery disease 
Carotid artery symptoms can be classified to hemispheric or retinal. Hemispheric 
symptoms include hemi-motor/sensory signs and/or evidence of higher cortical 
dysfunction (dysphasia, visuospatial neglect, etc). This could be in form of stroke 
which is defined as a focal (occasionally global) loss of cerebral function lasting 
>24 hours, or a transient ischaemic attack (TIA) which has a similar definition but 
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the deficit lasts <24 hours. Retinal symptoms comprise transient monocular 
blindness (amaurosis fugax) or permanent monocular visual loss following central 
retinal artery occlusion (equivalent to a stroke). The term ‘crescendo’ TIAs is used 
when the patient suffers repeated neurological events with complete recovery in 
between. 
 
1.1.3 Radiological investigations of CAD 
There have been many studies on the ability of radiological investigations to 
identify features of plaque instability as well as assessing and detecting 
atherosclerotic arterial disease. Colour-assisted duplex ultrasound is an 
important imaging modality for assessing patients with carotid artery disease. It 
is recommended as a first line investigation for carotid disease (Naylor, et al., 
2017). It is non-invasive, safe and inexpensive. It has a sensitivity and specificity 
for 70 to 90% stenosis of 0.89 and 0.84 respectively while they are 0.36 and 0.91 
for 50 to 69% stenosis (Wardlaw, et al., 2006). 
 
Contrast-enhanced ultrasound can further evaluate carotid stenosis morphology 
and possibly neovascularization of plaque. Although this is promising for 
predicting plaque instability, it is not widely used and has to be standardized and 
proven in prospective studies (Shalhoub, et al., 2010). The recommended criteria 
for ultrasound evaluation of carotid stenosis is based on the NASCET 
measurement method. It includes recording the peak systolic velocity (PSV) and 
the end diastolic velocity (EDV) in both internal carotid artery (ICA) and common 
carotid artery (CCA), then measuring their ratios to determine degree of stenosis 
(table 1) (Oates, et al., 2009).  
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Magnetic Resonance Angiography (MRA), on the other hand, is less operator 
dependent and produces an image of the whole artery. Contrast enhanced MRA 
has the ability to produce a three-dimensional image of the carotid bifurcation 
with good sensitivity and specificity for detecting high-grade carotid stenosis (0.94 
and 0.93, respectively, for stenosis of 70 to 90%, and 0.77 and 0.97, respectively, 
for stenosis of 50 to 69%) (Wardlaw, et al., 2006). MRA has been considered a 
promising modality for predicting plaque instability by detecting the presence of 
a large necrotic core, the amount of intraplaque haemorrhage and the presence 
of ulcerated or thinned plaque cap (Kerwin, et al., 2013) (Wasserman, 2010). 
 
Positron Emission Computerised Tomography (PET/CT) scanning has shown 
some promise as a mean for assessment of plaque instability (Sakalihasan & 
Michel, 2009). It has been used to allow in vivo identification of local activity 
related to altered or increased cell metabolism in the arterial wall which may be 
associated with plaque instability (Wu, et al., 2007) . However, it is expensive, not 
widely available and has the disadvantage of the exposure to ionising radiation 
which makes it difficult to carry out serial assessments (Mofidi & Green, 2014). 
 
% Stenosis PSV ICA (cm/s) 
PSV (ICA) / PSV 
(CCA) ratio 
PSV (ICA) / EDV 
(CCA) ratio 
< 50% <125 <2 <8 
50 – 69 % ≥125 2 – 4 8 – 10 
60 – 69 % ≥125 2 – 4 11 – 13 
70 – 79 % ≥230 ≥4 14 – 21 
80 – 89 % ≥230 ≥4 22 – 29 
> 90% ≥400 ≥5 ≥30 
Near occlusion String flow Variable Variable 
Occlusion No flow No flow No flow 
Table 2: NASCET criteria for carotid artery stenosis evaluation (Oates, et al., 2009) 
 
 
30 
 
 
1.1.4 Management of carotid artery disease 
 
1.1.4.1 Best medical therapy 
Best medical therapy is centred around reversible risk factors of atherosclerosis 
with the emphasis on the anti-inflammatory effect of some pharmaceutical agents 
on the progress of plaque. Patients who present with TIA symptoms should be 
started on risk factor medications, which may reduce their risk of stroke within the 
following 90 days for up to 80% (Rothwell, et al., 2007). 
 
1.1.4.1.1 Antiplatelet therapy 
Antiplatelet therapy is one of the most important interventions to reduce the odds 
of recurrent stroke or TIA by up to 22% (Intercollegiate Stroke Working Party of 
the Royal College of Physicians of London, 2016). Early studies suggested that 
aspirin (Cyclooxygenase pathway inhibitor) could reduce the risk of long term 
stroke by up to 25% (Antiplatelet Trialists' Collaboration, 1994). There is also 
evidence that the use of aspirin and dipyridamole combined reduces the risk of 
late stroke significantly compared with either of them alone (Diener, et al., 1996) 
(ESPRIT Study Group, 2006). 
 
ADP inhibitors monotherapy (Clopidogrel, Dipyridamole and Ticlopidine) has also 
been used, with strong evidence suggesting that clopidogrel significantly reduces 
the risk of stroke compared to aspirin monotherapy  (CAPRIE Steering 
Committee, 1996). However, combining aspirin and dipyridamole was found to 
be as effective as clopidogrel monotherapy (ESPRIT Study Group, 2006) 
(PRoFESS Study Group, 2008). Although, there is no evidence that adding 
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aspiring to clopidogrel has any advantage compared to clopidogrel monotherapy, 
with evidence of increased bleeding risk when using both (Diener, et al., 2004). 
It is therefore recommended that the standard antiplatelet treatment to reduce the 
risk of recurrent ischaemic stroke or TIA should be clopidogrel 75mg daily as a 
first line. If clopidogrel is not tolerated, aspirin 75mg daily with dipyridamole 
200mg twice daily should be used instead (Intercollegiate Stroke Working Party 
of the Royal College of Physicians of London, 2016). 
 
In asymptomatic carotid disease, however, there is conflicting evidence regarding 
antiplatelet therapy. Early studies on aspirin effect on patients with asymptomatic 
carotid disease suggested no difference in any ischaemic events or death when 
using aspirin (Côté, et al., 1995). More recent studies in contrast associated 
antiplatelet therapy with lower rates of stroke and death in patients with 
asymptomatic 70-99% carotid stenosis (King, et al., 2013). It is currently 
recommended to use aspirin 75-325mg daily as a first line antiplatelet therapy in 
patients with asymptomatic carotid stenosis to reduce the risk of myocardial 
infarction and other cardiovascular events, with clopidogrel reserved for patients 
with aspirin intolerance (Naylor, et al., 2017). 
 
1.1.4.1.2 Lipid lowering therapy 
There is growing evidence that the effect of statins is not just cholesterol lowering 
but they also thought to have a role in carotid plaque stability. The UK Heart 
Protection Study suggested a relative risk reduction of 25 % in stroke and 17% in 
vascular death when using simvastatin 40mg daily (Heart Protection Study 
Collaborative Group, 2011). Other studies suggested that there is a relative risk 
reduction of 15% in stroke when using atorvastatin 80mg daily (Amarenco, et al., 
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2006). Based on these two studies, it is recommended to use statin therapy with 
atorvastatin 80mg daily in the management of patients with ischaemic stroke or 
TIA (Intercollegiate Stroke Working Party of the Royal College of Physicians of 
London, 2016). 
 
Statin therapy is also currently recommended in patients with asymptomatic 
carotid stenosis to reduce the risk of stroke (Halliday, et al., 2010). However, so 
far there is insufficient evidence regarding the dosage and intensity of statins 
(Naylor, et al., 2017). 
 
1.1.4.1.3 Blood pressure control 
There is a considerable controversy around the role of blood pressure control on 
the risk of stroke. However, there is enough evidence to suggest that the use of 
Angiotensin-Converting Enzyme Inhibitors (ACEi) does lower this risk. Two large 
randomised trials (PROGRESS and HOPE) studied the effect of ACEi on the risk 
of stroke in patients with history of ischaemic stroke or TIA (PROGRESS) or 
vascular disease (HOPE). PROGRESS suggested a relative risk reduction of 
28% at 4 years when using perindopril 4mg daily (PROGRESS Collaborative 
Group, 2001), while HOPE suggested a 32% relative risk reduction in stroke 
when using ramipril 10mg daily  (The Heart Outcome Prevention Evaluation 
Study Investigators, 2000). 
 
It is currently recommended that patients who had an ischaemic stroke or TIA 
should maintain their systolic blood pressure <130mmHg to effectively reduce 
their risk of recurrent stroke (Intercollegiate Stroke Working Party of the Royal 
College of Physicians of London, 2016). Although there are no randomised trials 
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to study the effect of blood pressure control on preventing stroke in patients with 
asymptomatic carotid stenosis, it is still recommended to maintain their blood 
pressure <140/90mmHg, based on a meta-analysis of 25 blood pressure 
randomised controlled trials (Naylor, et al., 2017). 
 
1.1.4.2 Surgical and endovascular interventions 
Randomised controlled trials on managing carotid artery disease have suggested 
treating symptomatic carotid disease (50-99% stenosis) with carotid 
endarterectomy with the maximum benefit in patients with 70-99% stenosis, 
provided the peri-operative risks do not exceed the benefits from this intervention 
(North American Symptomatic Carotid Endarterectomy Trial Collaborators 
(NASCET), 1991). 
 
Table 3 summarises the results from three large trials (European Carotid Surgery 
Trialists’ Group 1998; North American Symptomatic Carotid Endarterectomy Trial 
NASCET 1998; and the Veteran Affairs Trial 1991), comparing best medical 
therapy (BMT) to carotid endarterectomy (CEA) in symptomatic carotid disease. 
(Naylor, 2015). 
 
 5 years ipsilateral stroke prevention 
Stenosis BMT CEA 
<30% 9.8% 12.1% 
30-49% 18.1% 14.8% 
50-69% 18.2% 13.6% 
70-99% 26.2% 10.4% 
Table 2: Comparison of BMT and CEA (Naylor, 2015) 
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However, controversy arises in asymptomatic carotid disease. A large 
randomised trial from the USA (ACAS 1995) strongly recommended carotid 
endarterectomy in asymptomatic lesions causing > 60% stenosis. However, data 
from this trial and another large randomised trial from the UK (ACST 2004) 
suggested that intervening on asymptomatic carotid stenosis may only provide a 
modest reduction in stroke risk from 2% per year to 1% per year (Executive 
Committee for the Asymptomatic Carotid Atherosclerosis Study, 1995) (MRC 
Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group, 2004). This 
was widely criticised, and the results of those two trials are probably too historical 
now to guide practice (Naylor, 2015). A second Asymptomatic Carotid Surgery 
Trial (ACST-2) and a second European Carotid Surgery Trial (ECST-2) are 
currently undergoing to try and answer this question. 
 
The question of whether modern medical therapy (including statins) is equivalent 
or superior to carotid endarterectomy or stenting was not yet been addressed by 
well-designed, appropriately funded, prospective, multicenter, and randomized 
trials (Ricotta, et al., 2001). Carotid artery stenting (CAS) is a more recently 
developed therapeutic alternative to carotid endarterectomy (CEA) for the 
treatment of carotid artery disease. It can be performed under sedation and 
preserves the cranial nerves which are at risk of palsy in CEA cases. 
 
The results from trials comparing the two in symptomatic patients have been 
conflicting (Rosenfield, et al., 2016). The use of stenting in asymptomatic patients 
has been studied in the Asymptomatic Carotid Trial (ACT I). Although the long-
term effectiveness of CAS is not inferior to that of CEA, however, the trial 
suggested a 30-day risk of stroke or death of 2.9% in stenting compared to 1.7% 
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with endarterectomy (Rosenfield, et al., 2016). Similar results were shown in the 
CREST trial too (Brott, et al., 2010). These results illuminate the fact that the peri-
procedure risk of stroke is almost twice as high with CAS than with CEA. 
Furthermore, many studies show that small silent infarctions (picked on diffusion-
weight MRI scan) are more common after CAS than after CEA, with some 
reporting micro emboli presence on transcranial doppler scan during stent 
placement (Spence, et al., 2016). 
 
The recommendation is that CAS should currently be considered for patients with 
indication for carotid revascularization and high surgical risk or unsuitable for 
open surgical, and patients who have a preference for stenting (Intercollegiate 
Stroke Working Party of the Royal College of Physicians of London, 2016) 
In general, most of the studies have shown that with modern intensive medical 
therapy the annual risk of stroke in patients with asymptomatic carotid artery 
disease is around 0.5% which is lower than either carotid artery stenting (CAS) 
or endarterectomy (CEA) (Marquardt, et al., 2010) (Naylor, 2011). This highlights 
the importance of identifying patients with asymptomatic carotid atherosclerosis 
and at high risk of stroke or death, so that we can offer them intervention before 
they develop symptoms. 
 
1.2 Peripheral artery disease in the lower limbs (PAD) 
PAD is a term used to describe the impairment of blood flow to the extremities 
usually as a result of atherosclerotic stenotic or occlusive disease (Schirmang, et 
al., 2009) (Flu, et al., 2010). Generally speaking, the presence of symptoms in 
PAD depends on the metabolic demands of the ischaemic tissue during exercise, 
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the degree of collateral circulation and the size and location of the affected artery 
(Hills, et al., 2009). 
 
The incidence of PAD varies in the general population from 3-10% in people 
younger than 70 years to 15-20% in people older than 70 years (Norgren, et al., 
2007). However, approximately 40% of PAD patients are asymptomatic, while 
only 10% of them present with typical intermittent claudication (Schirmang, et al., 
2009) (Hiatt, 2001). One third of PAD patients will have a complete occlusion of 
a major artery to the leg at first presentation (Norgren, et al., 2007) (Fowkes, et 
al., 1991). 
 
1.2.1 PAD morbidity and mortality 
Only about 25% of patients with intermittent claudication (IC) will significantly 
deteriorate, most frequently (7% to 9%) in the first year following diagnosis 
compared with 2% to 3% per year thereafter (Norgren, et al., 2007). The reported 
incidence of critical limb ischaemia (CLI) is around 200-400 new cases every year 
per million population (Rothwell, et al., 2004), and approximately 1 out of every 
100 patients with IC will present with CLI per year (Ubbink, 2004). 
 
Although major amputation is a relatively rare outcome of claudication, with only 
1% to 3% of claudicants needing it over a 5-year period (Norgren, et al., 2007), 
limbs with ulceration due to arterial insufficiency treated without revascularization 
will have a 19% risk of amputation at 6 months and 23% risk at 1 year (Marston, 
et al., 2006). Cardiovascular risk varies with the severity of PAD and is closely 
correlated to both reduced and increased ankle brachial pressure index (ABPI). 
The relationship between ABPI and mortality over a period of 10 years in the 
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Strong Heart Study is shown in figure 1 (Resnick, et al., 2004). Mortality in 
claudicants at 5, 10 and 15 years is 30%, 50% and 70% respectively and similar 
rates are found in asymptomatic patients. 25% of CLI patients will die within a 
year of diagnosis (Norgren, et al., 2007). 
 
 
Figure 1: All-cause and CVD morality according to ABPI group, SHS, 1988 to 1999, 
n=439 (Resnick, et al., 2004) 
 
1.2.2 PAD risk factors 
Similar to carotid artery disease, PAD risk factors can be divided into non-
modifiable (race, male gender and increasing age) and modifiable (smoking, 
diabetes mellitus, hypertension and dyslipidaemia). Other modifiable risk factors 
for PAD include hypercoagulable and hyperviscous states; 
hyperhomocysteinaemia; systemic inflammatory conditions and chronic renal 
insufficiency (Norgren, et al., 2007). Overall, PAD increases with smoking, 
African-American ethnicity, renal insufficiency, diabetes mellitus, and 
hypercholesterolaemia (Selvin & Erlinger, 2004) while it has been documented 
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that developing critical limb ischaemia (CLI) is more likely with ABPI of less than 
0.7, age over 65 years, smoking, and hypercholesterolaemia (Hirsch AT, 2006). 
 
1.2.3 Clinical presentation of PAD and classification 
Although 65-75% of patients with PAD are asymptomatic, the classic presenting 
symptom is intermittent claudication which is usually described as muscle 
cramps, fatigue or pain in the lower legs induced by exercise and rapidly relieved 
by rest; often the symptom location indicates the level of arterial involvement 
(Schirmang, et al., 2009). Less commonly, patients may present with critical limb 
ischaemia. The European Society of Vascular Surgeons defined CLI as a 
recurring ischaemic rest pain requiring analgesia for more than two weeks or 
ulceration or gangrene of foot or toes with ankle systolic pressure < 50 mmHg or 
toe systolic pressure < 30 mmHg (Fontaine’s III and IV) (Norgren, et al., 2007). 
 
Fontaine’s classification, proposed in 1954, remains a popular way of staging 
PAD. It divides patients into groups according to their clinical presentation. A 
similar clinical classification developed more recently by Rutherford has the 
advantage of including haemodynamic data, helping to ensure that any rest pain 
or tissue loss is directly related to PAD (Table 3) (Becker, et al., 2011). 
 
Another classification of PAD could be made according to the duration of 
symptoms. Patients could present with Acute Limb Ischaemia (less than 24 hours 
duration), Sub-acute Limb Ischaemia (more than 24 hours and less than two 
weeks) or Chronic Limb Ischaemia (symptoms more than two weeks in onset). 
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Fontaine’s Rutherford’s 
Stage Clinical presentation Stage Clinical presentation 
I Asymptomatic 0 Asymptomatic 
II Intermittent claudication 1 Mild claudication 
 
IIa - on walking > 200 m 2 Moderate claudication 
IIb - on walking < 200 m 3 Severe claudication 
III Rest pain 4 Rest pain 
IV Ulceration or Gangrene 
5 Minor ischaemic ulceration  
6 
Severe ischaemic ulcers or 
frank gangrene 
Table 3: Fontaine’s and Rutherford’s classification of PAD 
 
1.2.4 Radiological diagnostic investigations for PAD 
Colour-assisted duplex ultrasound scan is safe, non-invasive and non-expensive 
and, if done by an expert hand, able to provide anatomical as well as functional 
information (Norgren, et al., 2007). It is often used in surveillance following 
angioplasty or reconstruction. However, the accuracy of this investigation is 
highly operator-dependent. Other disadvantages include the length of 
examination and the challenge in imaging crural arteries. 
 
Magnetic resonance angiography (MRA) and computed tomography angiography 
(CTA) could be used to confirm and localise suspected disease, especially where 
intervention is being considered. Both techniques have been shown to be 
sensitive and specific for PAD evaluation (Catalano, et al., 2004). They are similar 
in terms of diagnostic accuracy, clinical outcome and ease of use (Ouwendijk, et 
al., 2005). 
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Although MRA is a more expensive investigation than CTA, it has the advantage 
of avoiding the nephrotoxic iodinated contrast material and radiation, as well as 
the ability to provide rapid high-resolution 3D images of the abdomen, pelvis and 
lower limbs in one setting. As a result, MRA has become the preferred imaging 
technique for the diagnosis and treatment-planning of patients with PAD in many 
centres. However, MRA is contraindicated in patients with implanted devices 
such as pacemakers and metallic clips and in those with claustrophobia 
(Ouwendijk, et al., 2005). Previous arterial stents cause signal dropout making 
assessments of patency or in-stent stenosis difficult. In addition, a retrospective 
study showed a link between the contrast agent used for MRA, gadolinium, and 
nephrogenic systemic fibrosis (NFS) (Sadowski, et al., 2007). 
 
Even though catheter-based digital subtraction angiography is considered the 
‘gold standard’ investigation for PAD (Norgren, et al., 2007) (Sritharan & Davies, 
2006), this is usually only performed when a concurrent endovascular 
intervention is anticipated due to its invasive nature. The risks related to catheter 
angiography include nephrotoxicity induced by the iodinated contrast, allergic 
reaction to the contrast, arterial dissection, arterial spasm, embolization and 
access site complications such as haematoma, pseudoaneurysm and arterio-
venous fistula (Norgren, et al., 2007). 
 
The use of non-toxic contrast agents such as gadolinium (Waybill & Waybill, 
2001) and carbon dioxide (Hawkins, et al., 2009) has been recommended in 
patients with renal impairment to reduce the risk of nephrotoxicity seen with 
conventional contrast media (Aspelin, et al., 2003). 
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The National Institute for Health and Care Excellence in the UK (NICE) 
recommended duplex ultrasound as first-line imaging to all people with peripheral 
arterial disease for whom revascularisation is being considered. It further 
recommended to offer contrast-enhanced magnetic resonance angiography (or 
CTA if MRA is contraindicated) to patients with PAD who need further imaging 
(after duplex ultrasound) before contemplating revascularisation (NICE, 2012). 
 
Considering the progressive occlusive disease aetiology of PAD, these 
investigations can help in assessing the severity of atherosclerotic stenosis or the 
presence of occlusion in the arteries, which will then allow the prediction and 
evaluation of PAD prognosis, as well as planning interventions when indicated. 
 
1.3 Carotid plaque morphology and plaque instability 
The development of atherosclerosis commences in the teenage years as a result 
of endothelial dysfunction with formation of a fatty streak, an inflammatory lesion 
that affects the intima, causing the formation of foam cells. This progresses with 
time to development of a fibro-proliferative atheroma and finally advanced lesion, 
containing a necrotic lipid core covered by a fibrous cap which may thin and 
rupture (Bartholomew & Olin, 2006). Acute events associated with carotid 
atherosclerosis are caused by plaque rupture and the creation of a thrombus 
rather than its haemodynamic effect on the arterial blood flow. Studies have also 
suggested that carotid and femoral plaques show different morphology in 
comparable groups of patients (Herisson, et al., 2011). 
 
Although, changes in plaque morphology precede symptoms, understanding of 
the underlying pathophysiology is still inadequate. However, carotid plaque 
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instability has been well described histopathologically and there are different 
classifications of atherosclerotic lesions in place. Every plaque has a fibrotic cap 
containing lipid-filled macrophages, collagen and smooth muscle cells, and a 
core of necrotic mass and lipids. The progression of plaques (Figure 2) starts with 
an initial damage to the endothelium which increases the permeability of the 
intima to lipoproteins that leads to the formation of fatty streak (DiCorleto & 
Chisolm, 1986). Subsequent development and breakdown of lipoproteins result 
in the invasion of leucocytes into these fatty streaks to hunt for the breakdown 
products which in turn converts them into lipid-rich macrophage foam cells, 
resulting in the formation of atheroma (Stary, et al., 1995). The atheroma then 
acquires a lipid-rich necrotic centre from foam cell apoptosis and a surrounding 
fibrotic layer evolved from the proliferation of the smooth muscle cells within the 
intima (Fostegard, et al., 1990). More advanced lesions then occur with the help 
of neo-vascularisation of the atheroma (Virmani, et al., 2000). 
 
 
Figure 2: Plaque progression (Stary, et al., 1995) 
 
The American Heart Association classified atherosclerotic lesions according to 
their histological progress into 6 types (Table 4) (Stary, et al., 1995). 
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Type I Initial lesion 
Type II Type IIa Progression-prone type II lesion 
Type IIb Progression-resistant type II 
Type III Intermediate lesion (pre-atheroma) 
Type IV Atheroma 
Type V Type Va Fibroatheroma (type V lesion) 
Type Vb Calcific lesion (type VII lesion) 
Type Vc Fibrotic lesion (type VIII lesion) 
Type VI Lesion with surface defect, and/or hematoma-
hemorrhage, and/or thrombotic deposit 
Table 4: Terms Used to Designate Different Types of Human Atherosclerotic Lesions in 
Pathology 
 
Further histological studies have shown more manifestation of fibrous cap 
atheroma and cholesterol in carotid plaques compared to more fibrocalcific 
plaque in femoral arteries, with morphological studies also showing a higher 
prevalence of osteoid metaplasia in femoral arteries (Herisson, et al., 2011). 
 
1.3.1 The unstable plaque 
Unstable plaques have certain features including an intense inflammatory 
process within the plaque, angiogenesis, and intra-plaque haemorrhage with 
gradual thinning of the fibrous cap, subsequent loss of plaque cap integrity and 
ulceration (Mofidi & Green, 2014). 
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1.3.1.1 Inflammation 
Inflammation is thought to play an important role in the initiation, the progression 
and the instability and rupture of plaques (Libby, 1995). Studies suggest that 
mature plaques contain variable amounts of inflammatory cells, concentrated 
mainly in lipid-rich lesions that can be found in the thinned cap or/and the 
shoulders of the lesions (Davies, et al., 1993).  The presence of monocyte-
derived macrophages and T-lymphocytes at the site of plaque rupture has been 
well documented (Koenig & Khuseyinova, 2007). These inflammatory cells have 
the ability to produce cytokines, chemokines, and growth factors, which lead to 
the proliferation of smooth muscle cells, plaque progression and the degradation 
and weakening of the fibrotic cap (Shah, 2003). 
 
When compared to femoral plaques, carotid plaques have more macrophages 
and T-cells which is consistent with a more inflammatory phenotype. Moreover, 
symptomatic carotid plaques predominantly display M1-macrophages 
(macrophages that encourage inflammation), while femoral plaques mainly have 
M2-macrophages (macrophages that decrease inflammation and encourage 
tissue repair) (Shaikh, et al., 2012). 
 
1.3.1.2 Angiogenesis 
The presence of newly formed blood vessels (angiogenesis) has been described 
as part of the plaque development (O'Brien, et al., 1994). In addition, the density 
of these vessels in carotid plaques has been linked with plaque instability and 
intra-plaque haemorrhage (Virmani, et al., 2006). 
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More importantly, angiogenesis is considerably increased in carotid plaques from 
symptomatic patients compared to asymptomatic plaques (McCarthy, et al., 
1999). 
 
It is also thought that symptomatic carotid plaques have larger, more irregular 
and immature newly-formed vessels, which makes them more prone to 
haemorrhage and eventually plaque rupture (Folkman, 1995). Although it has 
been suggested that the lipid core in the plaques can be the stimulator of the 
angiogenesis process (Silverman, et al., 1985),  it is difficult to explain the 
absence of angiogenesis in some asymptomatic carotid plaques when examined 
histologically (McCarthy, et al., 1999). 
 
1.3.1.3 Intra-plaque haemorrhage and cap thinning 
Many studies have shown that intraplaque haemorrhage is associated with 
plaque instability and the occurrence of neurological events, with some reporting 
its presence in up to 95% of ruptured plaques (Carr, et al., 1996). It is thought 
that intraplaque haemorrhage leads to rapid changes in plaque volume and the 
necrotic core which increases plaque instability risk (Von Maravic, et al., 1991). 
Although the source is uncertain, intraplaque haemorrhage may occur from 
fissures within the cap which allows the entrance of blood into the plaque (Davies 
& Thomas, 1985), or as a result of the rupture of newly-formed vessels within the 
plaque with some studies recording an increased vessels density correlating with 
the presence and amount of intraplaque haemorrhage (Moreno, et al., 2006) 
(Türeyen, et al., 2006). 
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1.3.2 Predicting plaque instability 
Predicting changes in advanced atherosclerotic lesions before the event occurs 
has always been a great challenge with most available screening and diagnostic 
methods being insufficient.  Identification of biomarkers of plaque instability could 
allow early recognition of disease, and consequently preventative measures 
could be applied to avoid acute events and reduce atherosclerosis related 
mortality, morbidity and cost of treatment of advanced disease. 
 
Many studies have attempted to find reliable, accurate and easy to detect 
biomarkers of atherosclerosis. C-Reactive Protein has been suggested in a few 
studies as a potential biomarker and yet its value in our clinical practice is yet to 
be proven, mainly because of its lack of specificity (Koenig & Khuseyinova, 2007). 
Non-invasive detection of radio-labelled Annexin A5 - a plasma protein with a 
strong affinity for phosphatidylserine expressed by apoptotic cells - has been 
explored as a technique that can predict carotid plaque instability in studies with 
only small number of patients (Kietselaer, 2004) (Corsten, et al., 2007). 
 
The use of different imaging modalities to predict plaque changes and instability 
in asymptomatic patients has also been investigated thoroughly over the last two 
decades. These modalities mainly focused on detecting carotid plaque ulceration 
as a key feature for plaque instability (Yuan, et al., 2017). Although each modality 
may be able to detect a variety of plaque instability characteristics, none can 
identify and reliably predict all of them (De Feijter & Nieman, 2011). 
Metabolomic and proteomic profiling has become an increasingly used and 
powerful technique for the detection of biological markers of disease (Rochfort, 
2005). 
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Not many studies have assessed atherosclerotic arterial disease using plasma 
or urine samples from patients with symptomatic atherosclerotic disease in 
addition to plaque extraction to identify potential biomarkers. Analysing plaques 
without extraction (solid state tissues) is still in its infancy and, supported by very 
promising results from trials on cancerous cells, could well provide realistic, 
reliable and clinically valuable biomarkers, provided these markers can be 
measured systemically. 
 
1.4 The “Omics” era 
The Omics science includes proteomics, genomics and metabolomics. While 
genomics and proteomics provide extensive information regarding the genotype, 
they give quite limited information regarding molecular phenotype. One major 
problem with these types of studies is reproducibility and several efforts to 
improve it have been published (Boja & Rodriguez, 2012). 
 
Mass spectrometric analysis is usually used to detect a mixture of the large 
number of proteins in biological samples to identify potential biomarkers of a 
disease (Proteomics studies). Due to the wide range of proteomics obtained from 
each sample and considering its low reproducibility rate, it is becoming 
increasingly important to study targeted proteomics to help in understanding 
mechanisms and pathways of the disease (Boja & Rodriguez, 2012). 
 
Metabolomics studies on the other hand looks into low molecular weight 
composites in a sample or tissue which are the closest link to phenotype (Wishart, 
2007). It is a newer ‘omics’ science that can establish differences between 
healthy and diseased samples in their metabolomic profiling. 
48 
 
 
Nuclear Magnetic Resonance (NMR) Spectroscopy has the ability of detecting 
almost all the metabolites in a sample. It is a non-invasive technique that allows 
repeated measurements with the great value of reproducibility and analysing 
intact tissues. However, NMR sensitivity has always been an issue and one way 
to increase it is by using higher resonance frequency to reduce the amount of 
noise affecting signals. Availability of such devices, in addition to their costs, has 
limited research projects carried out in this field. 
 
1.4.1 Metabolomics 
The metabolome was first described by Oliver and colleagues as “the quantitative 
complement of all of the low molecular weight molecules present in cells in a 
particular physiological or developmental state” (Oliver, et al., 1998). Metabolites 
are regarded as the end product of metabolism, and there is an estimate of at 
least 3000 metabolites in the human metabolome (Dunn, et al., 2007) (Lewis, et 
al., 2008). 
 
Metabolomics or metabolic profiling can be defined as “the quantitative 
measurement of the metabolic response of living systems to pathophysiologic 
stimuli or genetic modification” (Goodacre, et al., 2004) (Nicholson, et al., 1999). 
Living systems always try to preserve homeostasis when exposed to a stimulus 
(disease, drugs, etc). This disturbs the normal ratio of metabolites and changes 
the biofluid and tissue profile (Lindon, et al., 2006). Metabolite normal ratio is 
precise to each individual, but the loss of homeostasis is considered to be the 
first stage of disease progress (Van Der Greef & Smilde, 2005). 
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The difference between metabolomics (with “L”) and metabonomics (with “N”) is 
still arguable but most nuclear magnetic resonance (NMR) spectroscopy 
researchers initially used the later terminology. Metabolomics is mainly 
concerned with profiling all metabolites in normal conditions, while metabonomics 
expands it to include biochemical distress caused by a disease or drug 
(Hollywood, et al., 2006). In practice, however, there is a great degree of 
overlapping between the two terms and they are essentially identical (Robertson, 
2005). 
 
The term “Metabolomics” will be used in this report as it is now more commonly 
used amongst researchers. 
 
1.4.2 The use of NMR in metabolic profiling 
Although the idea of metabolic profiling was introduced a long time ago (Gates & 
Sweeley, 1978), it was only through technological analytical innovations in recent 
decades, namely gas chromatography-mass spectrometry (GC-MS), that  
quantitative measurement could be performed (Van Der Greef & Smilde, 2005). 
Also, the immense advances in the science and technology of nuclear magnetic 
resonance (NMR) spectroscopy in the last two decades permitted its use in the 
field of metabolic profiling (Emwas, 2015). Nicholson and colleagues were the 
first to explain metabolomics and they further established the application of 
pattern recognition techniques to data obtained from NMR spectroscopy (Lenz & 
Wilson, 2007) (Nicholson, et al., 1999) (Nicholson, et al., 1984). 
 
Nowadays, NMR spectroscopy alongside mass spectroscopy (combined with 
liquid chromatography mass spectrometry LC-MS or gas chromatography mass 
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spectrometry GC-MS) are widely used in metabolic profiling. Each has its 
advantages and disadvantages and joining the two would provide more detailed 
analysis (Fancy, et al., 2006). 
 
Table 5 summarises the main differences between NMR and MS (Viant, et al., 
2009) (Lindon & Nicholson, 2008) (Emwas, 2015). 
 
 NMR MS 
Reproducibility High Low 
Sample preparation Easy Difficult 
Sample preservation Good Poor 
Sensitivity Low High 
Metabolic recognition Universal Narrow 
Separation techniques Always the same Variable 
Table 5: Advantages and disadvantages of NMR vs MS 
 
Although there has been a significant improvement in NMR sensitivity, this 
remains its weakest point, and it can sometimes limit the detection of low 
molecular weight metabolites (Emwas, 2015) (Dunn, et al., 2007). This mainly 
occurs because they are masked by either the large water signal associated with 
biofluids, or high molecular weight metabolites activities within the magnetic field. 
Though, adjusting pulse sequences can potentially minimise the effect of these 
two problems when studying low molecular metabolites (Saude, et al., 2006). 
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1.4.3 Nuclear Magnetic Resonance (NMR) Spectrometry 
 
1.4.3.1 Brief history 
NMR was first described by Isidor Rabi in 1938 and he was awarded the Nobel 
Prize in Physics for his work in 1944. The use of the technology on liquids and 
solids was then introduced in 1945 by 2 independent groups of physicists – Bloch 
and colleagues at Stanford University and Purcell and colleagues at Harvard. 
They also shared the Nobel Prize in Physics in 1952. Jacobson and colleagues 
carried out the first biological investigation using NMR technology in 1954. Since 
1960, the technology has been routinely applied in organic chemistry for 
molecular structuring with major advances happening since the 1970s including 
computing and pulse-Fourier transform methods. 
 
High resolution NMR spectroscopy has recently been widely used in identification 
of biomarkers of disease, while using Magic Angle Spinning for tissue analysis 
has allowed monitoring dynamic processes and giving information on 
compartmentisation. 
 
1.4.3.2 Principles of NMR spectroscopy 
When nuclei are exposed to a magnetic field, they absorb and reproduce 
electromagnetic energy. The strength of this magnetic field (in Hertz) and the 
properties of the nuclei determine the resonance frequency of this energy. The 
use of NMR as an analytical tool allows examining these magnetic properties of 
the nuclei by the application an external magnetic field (Bo) and further agitating 
it by an electromagnetic pulse, usually a perpendicular 90o radio frequency (RF) 
pulse (Claridge, 1999). 
52 
 
 
All Isotopes have a specific number of protons and neutrons which affects the 
stability of the nucleus. When the spins of the protons and neutrons are not 
balanced, the overall spin (I) generates a magnetic dipole along the spin axis, 
and this is called the nuclear magnetic moment (µ). Therefore, the isotopes that 
contain an even number of protons and neutrons have an overall spin of zero, 
while isotopes with an odd number of either or both have a central and rotational 
magnetic moments which make them of nonzero spin (half integer spin and an 
integer spin respectively). Examples shown in table 6. The two most commonly 
used isotopes for NMR studies are 1H and 13C. (Skoog, et al., 1998). 
 
No or protons No of neutrons Spin quantum number (I) Examples 
Even Even 0 12C, 16O, 32S 
Odd Even 1/2 1H, 19F, 31P 
Even Odd 1/2 13C 
Odd Odd 1 2H, 14N 
Table 6: Examples of different spin quantum numbers of isotopes based on their proton 
and neutron numbers 
 
1.4.3.2.1 Principle of relaxation 
In quantum mechanics, when applying an external magnetic field (Bo) on a 
nucleus with an overall spin I, its nuclear magnetic moment will have (2I+1) 
possible orientations, either strengthen or oppose Bo. This means the energy 
levels split and each can be given a magnetic quantum number (m). (figure 3) 
(Claridge, 1999). 
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Figure 3: Energy splitting under the effect of external magnetic field Bo 
 
The magnetic moment of a nucleus in the lower energy level does not oppose 
Bo, and its axis of rotation will precess around the magnetic field. The frequency 
of this precession is called Lamor frequency. On the other hand, a nucleus in the 
higher energy level will oppose Bo and absorb the energy, which then changes 
the angle of precession. The ‘bulk magnetisation vector’ represents the 
combination of all vectors for nuclei. The rotation of this bulk vector under the 
effect of RF pulse changes from axis z towards the x-y plane (figure 4) (Edwards, 
2009) (Derome, 1987). 
 
When agitating these nuclei which make up the bulk magnetisation for the correct 
length of time, those energy levels may become equal and no further absorption 
of radiation will happen. This is called saturation (Claridge, 1999). Therefore, 
relaxation process comes into function to ensure the return of nuclei to the lower 
energy level (Derome, 1987). 
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Figure 4: Change of bulk magnetisation vector rotation under the effect of a 
perpendicular RF pulse 
 
There are two main relaxation processes; spin-lattice (Longitudinal) and spin-spin 
(transverse). Spin-lattice relaxation happens because of the interaction between 
nuclei in the higher energy level and the components of the lattice field caused 
by motion of neighbouring nuclei. This leads to energy loss and recovery to the 
ground state. The time needed for this is called longitudinal relaxation time (T1). 
Spin-spin relaxation happens because of the interaction between the 
neighbouring nuclei allowing the transfer of energy amongst them. All spins will 
have a similar frequency under the same Bo, but different magnetic quantum 
states due to the inhomogeneity of Bo. Therefore, some spins will be exposed to 
greater magnetic fields depending on its region (isochromat) within the sample 
and will process quicker than others. Transverse relaxation time (T2) permits the 
equalisation of all vectors and a zero-net magnetisation eventually (Claridge, 
1999) (Derome, 1987).  
 
Ideally, relaxation rates should be fast enough to reduce saturation, without losing 
the NMR spectra by being too fast (Claridge, 1999). To remove the Bo 
inhomogeneity effect and measure an accurate T2 value, 180o spin-echo pulse 
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sequence can be used. This helps with observing resonances from low molecular 
weight (LMW) molecules, which are normally much narrower than the high 
molecular weight (HMW) ones (Claridge, 1999) (Derome, 1987). An example of 
spin-echo pulse sequence is the Carr-Purcell-Meiboom-Gill (CPMG) sequence 
which will be used in this research. The Carr-Purcell pulse sequence uses many 
repetitions of short inter-pulse delays (τ) and 180o pulses resulting in the intensity 
of the echoes decaying according to T2 but because of the large number of 
echoes, the loss between each echo due to diffusion is small (Derome, 1987). 
 
1.4.3.2.2 NMR spectra 
The basis of obtaining NMR spectra depends upon the fact that large molecules 
have short T2 times, while small molecules have long T2 times (Derome, 1987). 
A typical NMR spectrum, therefore, contains thousands of sharp lines which 
correlate to different metabolites and vary according to these times and the 
sample used in the experiment. Urine samples, for example, have mainly low 
molecular weight metabolites, while plasma and serum samples usually have 
both low and high molecular weight metabolites with a wide range of signal line 
widths (Beckonert, et al., 2007). Examples of urine and blood NMR spectra are 
shown in figure 5 and figure 6. 
 
1.4.3.2.3 Chemical shifts 
Chemical shifts of the NMR frequency happen because of the ‘shielding’ effects 
of the electrons surrounding the nuclei. This causes the magnetic field at the 
nucleus to be different than the actual external magnetic field (Bo). This difference 
is called ‘nuclear shielding’. It allows, in turn, the exploration of the chemical 
structure of molecules. Chemical shifts are usually stated in parts per million 
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(ppm) to make it easier to illustrate the position of the resonances in an NMR 
spectra (Edwards, 2009) (Claridge, 1999) (Derome, 1987). 
 
 
Figure 5: 600 MHz 1H NMR spectrum of urine (Beckonert, et al., 2007) 
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Figure 6: 600 MHz 1H NMR spectrum of blood sample (Beckonert, et al., 2007) 
 
1.4.3.3 High resolution magic angle spinning NMR 
The advancements in high-resolution 1H magic angle spinning HR-MAS NMR 
spectroscopy has made it possible to gain high-resolution NMR data on small 
pieces of intact tissues (Garrod, et al., 1999). Rapid spinning of the sample at 
an angle of 54.7° helps reducing the loss of information caused by line 
broadening seen in nonliquid samples such as tissues (Beckonert, et al., 2007). 
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1.4.4 Data processing 
Metabolomics studies produce more measured variables than the actual number 
of samples (Trygg, et al., 2007). Thus, acquired data requires reduction, 
normalisation and scaling prior to analysing. This is mainly to allow accurate and 
adequate comparisons between the variables, and therefore make results 
amenable to multi-variate analysis (Craig, et al., 2006). 
 
1.4.4.1 Data reduction (Binning) 
This is usually achieved through the process of bucketing (binning). The spectra 
are divided into equal sized small bins to account for the small changes in 
chemical shifts between samples and to ensure comparable signals. The most 
commonly used bin size is 0.04 parts per million (ppm) (Craig, et al., 2006). Some 
studies used even smaller sizes to account for much smaller chemical shift 
differences (Holmes, et al., 1994) (Spraula, et al., 1994). The disadvantage of 
binning is that it sometimes can integrate two opposite peaks in the spectra, 
therefore not reflecting the intensity of either of them correctly (Jahns, et al., 
2009). 
 
1.4.4.2 Normalisation and scaling 
Data are usually organised in a table where each row is attributed to a certain 
sample or experiment, while the column reflects a particular measurement within 
that experiment.  
 
Normalisation of data is typically a table row operation while scaling is a table 
column one (Craig, et al., 2006). Normalisation is used to ensure data from all 
samples are comparable, commonly by removing the effect of varying dilution of 
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samples. The most common method is by normalising to the sum of the integrals 
of the whole spectrum, where each bin integral is divided by the spectrum integral 
and the sum of all the new integrals is set to one (Webb-Robertson, et al., 2005). 
 
Scaling, on the other hand, is used to express the variation in metabolites with 
low intensity. Mean-centering is often carried out prior to scaling to allow multi-
variate analysis of concentration variances around zero rather than around the 
concentration mean of metabolite (Van den Berg, et al., 2006). This can be done 
by subtracting the column mean from each value in it (Craig, et al., 2006). 
 
1.4.5 Previous NMR studies on atherosclerosis 
There have not been many NMR based metabolomic profiling studies 
investigating atherosclerotic biomarkers of carotid disease. No previous studies 
have used solid status NMR to compare intact plaques from various regions of 
the body and only four NMR based metabolomic studies have attempted to 
establish atherosclerosis biomarkers in mammalian models. 
 
1.4.5.1 Animal based studies 
Four animal studies used Nuclear Magnetic Resonance (NMR) technology to 
assess atherosclerotic metabolomes in hamsters and mice.  
 
Martin and colleagues carried out the first study examining the suitability of 
plasma metabolomics to determine the severity of diet-induced atherosclerosis in 
48 male Golden Syrian hamsters (Mesocricetus auratus), divided into six groups 
and fed with different experimental diets. Changes in amino acid and lipid 
metabolism associated with atherogenesis were demonstrated and animals were 
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able to be distinguished based on their dietary treatments. Promising 
atheropositive biomarkers (such as lipids and N-acetyl-glycoproteins) and 
atheronegative biomarkers (such as glutamine, proline, glycerol and creatine) 
were identified in this study, although they were thought to be valid only for the 
specific diets used in the study  (Martin, et al., 2009). 
 
Leo and colleagues studied NMR-based metabolomics of urine from 16 
apolipoprotein-E knockout mice. The mice were divided into two groups, 
captopril-treated and untreated. Urine samples obtained from the apolipoprotein-
E deficient mice were then analysed using 1H-NMR. The groups were able to be 
differentiated according to their NMR spectra and urine levels of xanthine and 
ascorbate were identified as potential markers of plaque formation (Leo & 
Darrow, 2009). 
 
Yang and colleagues studied the metabolomic profiling of 40 apolipoprotein-E 
knockout mice divided into four groups according to the duration of high fat 
feeding using 1H-NMR spectroscopy. The study suggested choline, glycine and 
glucose as potential biomarkers for the early diagnosis of atherosclerosis (Yang, 
et al., 2014). 
 
Li and colleagues were the first to analyse plasma, urine and tissue of western 
diet fed low density lipoprotein receptor knockout (LDLR-/-) mice, using both Gas 
Chromatography / Mass Spectrometry (GC-MS) and NMR spectrometry. 
Although, they did not identify a specific biomarker of atherosclerosis, they did 
identify that metabolisms of fatty acids and vitamin-B3 together with gut 
microbiota plays an important role in atherosclerosis development. This is 
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considered to be a novel molecular pathophysiological mechanism of 
atherosclerosis (Li, et al., 2015). 
 
Other animal studies mainly used mass spectroscopy technology. Mayr and 
colleagues identified 79 altered protein species during various stages of 
atherogenesis, using a combination of 2-dimentional gel electrophoresis and 
mass spectrometry profiling of aortas from apolipoprotein-E knock-out mice 
(Mayr, et al., 2005). 
 
Zha and colleagues studied metabolomic characterisation of early 
atherosclerosis in 24 Golden Syrian hamsters divided into three groups based on 
body weight, using Gas Chromatography / Mass Spectrometry (GC/MS). Twenty-
one compounds were identified as markers involved in the development to 
atherosclerosis with amino acid metabolism and fatty acid oxidation significantly 
being disturbed in the process (Zha, et al., 2009). 
 
While Zhang and colleagues used Ultra-Fast Liquid-Chromatography coupled 
with Ion Trap-Time of Flight (IT-TOF) Mass Spectrometry (UFLC/MS-IT-TOF) 
metabolomic approach to study the plasma and urine of 18 male Wistar rats 
allocated into two groups, high fat diet and common diet fed. Around 20 potential 
biomarkers were identified in the study. The results showed abnormal 
metabolism of bile acids, Lysophosphatidylcholines and amino acids in 
atherosclerosis rats (Zhang, et al., 2009). 
 
More recently, Jové and colleagues published a study on the plasma metabolome 
and circulating and aortic lipidome of 31 male Golden Syrian hamsters divided 
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into two groups (atherogenic diet vs normal diet), using Liquid Chromatography / 
Mass Spectrometry (LC/MS) analysis. The results showed the existence of 
several previously unreported changes in lipid and amino acid metabolism. 
Taurocholic acid, a sodium salt in the bile of mammals, was suggested as a 
potential plasma biomarker of early atheromatous plaque formation (Jové, et al., 
2013). 
 
1.4.5.2 Human based studies 
An early study using 1H-NMR analysis of human serum suggested that it was 
possible to predict the presence and severity of coronary artery disease (CAD) 
as more than 90% of CAD patients could be differentiated from patients without 
CAD from their metabolomic profiling (Brindle, et al., 2003). This has not been 
reproduced and subsequently challenged by a later study determining the 
predictive power of NMR for angiographically defined CAD. The study suggested 
that predictions for normal coronary arteries and diseased ones were only 
accurate in 61.3% of patients treated with statins (Kirschenlohr, et al., 2006). 
 
At least 24 metabolites were identified as significantly modified in the patients 
with atherosclerotic disease in a study which combined GC/MS and NMR 
spectroscopy to analyse metabolomics of plasma in humans with stable carotid 
atherosclerosis (n=9) compared with healthy controls (n=10). Those were mainly 
associated with the insulin resistance pathway (Teul, et al., 2009).  In another 
study using only GC/MS for metabolomics analysis of plasma from 16 patients 
with stable atherosclerosis compared with 28 healthy controls, researchers 
demonstrated that fatty acid metabolism, especially palmitate, could be a 
phenotypic biomarker for clinical diagnosis of atherosclerosis (Chen, et al., 2010). 
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In the Young Finns Study - a large epidemiological study of Cardiovascular Risk 
in 4309 subjects - data from serum NMR metabolomic spectral profiles were 
analysed to predict early atherosclerotic changes in healthy young adults. Three 
different metabolic phenotypes linked with high carotid intima-media thickness 
(IMT) were identified, all of which showed disturbances of lipid metabolism 
(Würtz, et al., 2011). 
 
Early attempts to combine proteomic and metabolomic techniques to reveal 
protein and metabolite alterations in individuals with atherosclerotic disease were 
encouraged by the fact that 2-D gel electrophoresis proved to be highly 
complementary to (NMR) spectroscopy (Mayr, et al., 2004). Only one study to 
date has used microparticles (MPs) derived from carotid artery plaques in 
patients undergoing carotid endarterectomy for metabolomic and proteomic 
analysis. Metabolomic study was done by liquid state HR-NMR spectroscopy 
while LC/MS was used for proteomic analysis. This study was the first to explore 
the protein distribution as well as metabolite content of MPs. Combining 
proteomics, metabolomics, and Immunomics had a great advantage and 
indicated to the role of MPs in inflammation, which is a key determinant of plaque 
instability (Mayr, et al., 2009). 
 
Jové and colleagues used LC/MS to analyse plasma samples from 131 TIA 
patients. The study identified lysophosphatidylcholine (LysoPC) as a potential 
biomarker of stroke recurrence, which will in turn enhance other predictive 
methods for stroke recurrence following TIA (Jové, et al., 2015). 
In a recent small study, organic and aqueous extracts obtained from carotid 
plaques in patients with symptomatic stenosis (n = 5) and asymptomatic stenosis 
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(n = 5) were analysed, using two ultra-performance liquid chromatography 
coupled to mass spectrometry metabolic profiling methods. The study showed a 
higher presence of metabolites related to the eicosanoid pathway (such as 
arachidonic acid and arachidonic acid precursors) in symptomatic patients 
(Vorkas, et al., 2016). 
 
1.5 Rationale of this study and expected value of results 
No studies have previously compared the results of metabolomic analysis of 
plasma, urine and plaques from the same subject. Also, no studies have 
attempted to define differences in the metabolic profile between patients with 
symptomatic and asymptomatic carotid artery disease to detect plaque instability 
or identify the “high risk patient”. 
 
Furthermore, no studies have compared metabolomic profiles of plaques and 
plasma from different origins (carotid vs femoral in this study). 
 
Finally, no studies have correlated data obtained from human samples to 
mammalian model of atherosclerosis, which is a worthy of investigation. 
 
In this research, we aim to study the metabolic profiles of human carotid 
atherosclerosis plaque, plasma and urine in patients with symptomatic carotid 
disease. We also intend to compare this to the metabolic profiles of human 
femoral atherosclerosis plaque, blood and urine in patients with claudication, and 
the metabolic profiles of human blood and urine in patients with no carotid 
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disease (control). In addition, this will be studied in a mouse model of 
atherosclerosis. 
 
We hope that this study may clarify the pathophysiological pathways involved in 
the final stages of development of plaque instability, and whether this is a local 
effect within the plaque or can be identified systemically in plasma or urine. 
Studies on a mammalian model of atherosclerosis may also guide future studies 
to further understand the disease mechanism and may lead to identification of 
novel therapeutic strategies targeted against development of plaque instability. 
 
This project could also advance the possibility of identifying a candidate 
biomarker for point-of-care risk assessment of stroke. This would potentially allow 
the development of a urine dipstick or blood test to identify high risk carotid 
plaques or high-risk patients who would most benefit from intervention to their 
carotid plaque prior to developing clinical symptoms. 
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Chapter 2: Design and methods 
 
2.1 Animal sample methods 
6 Apo-E knockout mice vs 6 Controls (Harlan-Olac, Bicester, UK) were used for 
the study). All mice were males and born on the 9th October 2011. All animals 
were fed high fat (western) diet until the 13th March 2012 (12 weeks). The 
apolipoprotein E–deficient (ApoE−/−) mouse is popular because of its tendency 
to spontaneously develop atherosclerotic lesions on a standard high fat diet (Meir 
& Leiterdorf, 2004). 
Animals were labelled as follow: 17X – 18X – 19X – 20X – 21X – 22X - 35C – 
36C – 37C – 38C – 39C – 40C. 
 
The housing and care of the animals, and all the surgical procedures carried out 
on them for this study, were in accordance with the UK Home Office regulations. 
Animals care, feeding and preparation was done by S Wheatcroft from the Leeds 
Institute of Cardiovascular and Metabolic Medicine (LICAMM) at the University of 
Leeds. Dr N Yuldasheva (from LICAMM) did the anaesthetising of the animals 
(by inhalation of Isoflurane with Oxygen), harvesting and samples acquisition, in 
addition to embedding solid tissue samples in paraffin ready for sectioning. 
 
2.1.1 Blood sample collection 
All blood samples were collected by Dr N Yuldasheva from the inferior vena cava 
of each animal. Approximately 900 µl was obtained from each animal. There were 
divided into 3 parts; 700 µl in Lithium heparinised (LH) tube, 100 µl in EDTA (ED) 
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tube and 100 µl in Citrate (Cit) tube (Figure 7). It was not possible to obtain any 
blood from animal 40C as the inferior vena cava collapsed immediately after 
cannulating and Dr N Yuldasheva was not able to aspirate any blood from it. 
Therefore, this was excluded from studies based on blood. 
 
Only plasma collected in LH tubes will be used in this study. All samples were 
centrifuged (eppendporf FBS29112 Centrifuge 5810 R) at 900 g for 10 mins 
within two hours of collection. Samples were kept in 4oC until processing. For 
samples collected in LH tubes, a minimum of 320 µl of plasma (supernatant) was 
obtained from each animal. Plasma was saved in aliquots in Eppendorf tubes 
(1.5ml micro tubes; Sarstedt; Leicester, UK, Ref: 72.690), then flash frozen in 
liquid nitrogen and stored in a freezer at −80°C until analysis. 
 
During preparation, samples 17X, 19X and 22X were mistakenly put into dry ice 
instead of 4oC ice prior to centrifuging and were therefore haemolysed. I was 
therefore not able to obtain plasma from these animals. There have been no 
studies using full blood samples instead of plasma in NMR metabolomic analysis, 
and if such analysis was tried then it will not be possible to carry out a valid like-
for-like comparison with the other plasma samples in this study. These 
haemolysed samples were still centrifuged (eppendporf FBS29112 Centrifuge 
5810 R) at 900 g for 10 mins and divided into 320μl aliquots (2 aliquots from each 
sample), flash frozen and stored at −80°C. 
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Figure 7: Blood sample collection from mice 
 
2.1.2 Tissue sample collection 
Tissue samples harvesting and embedding in paraffin was done by Dr N 
Yuldasheva. Animals were anaesthetised using Isoflurane with Oxygen and 
placed in supine position. A midline incision of chest and abdomen was 
performed, and internal organs were exposed. The inferior vena cava was 
cannulated and total blood volume was withdrawn. After the spontaneous 
stoppage of heart, the arch of aorta was harvested with the brachiocephalic, left 
common carotid and left brachial arteries attached to it. 
 
The brachiocephalic artery with part of the arch was then separated and saved in 
4% paraformaldehyde (PFA) for histological studies as recommended in previous 
studies (Johnson & Jackson, 2001) (Figure 8). The brachiocephalic is usually 
2 mm long with a diameter of 0.5 mm in mice, and reliably develops complex 
plaques (Bond & Jackson, 2011) (Rosenfeld, et al., 2000). 
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Due to its small size, it was not possible to harvest the actual plaques from the 
arch of aorta samples therefore I opted to store the whole sample intact. Arch 
samples were all flash frozen in liquid nitrogen then kept in -80oC. 
 
Left renal arteries were also harvested from the animals, flash frozen and stored 
at −80°C until required for analysis. This was due to reports in the literature 
regarding development of significant atherosclerotic plaques in renal arteries in 
Apo-E mice (Nakashima, et al., 1994). These samples will be later used to test 
and develop magic angle spinning NMR. 
 
Figure 8: Tissue sample collection from mice 
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2.2 Human sample methods 
 
2.2.1 Patient recruitment 
Ethical approval for studies carried out on human samples in this research was 
obtained in April 2012 from Yorkshire and the Humber NRES Committee 
(Reference 11/YH/0425). All patients were recruited from the vascular unit at 
Leeds General Infirmary between April 2012 till September 2013. Patients were 
approached at least 24 hours prior to recruiting. A patient information leaflet was 
given to all patients and written informed consent was obtained for inclusion in 
the study to allow laboratory tests on blood, urine and plaque samples. 
 
Patient demographics, vascular risk factors, other past medical history and 
medication history were recorded prior to sampling. Each patient was given a code 
according to the order of their recruitment, by using the preface (NMR) followed by 3-
digit number (Ex: NMR001-NMR002-...). 
 
2.2.1.1 Inclusion criteria 
All patients with 
- TIA (focal neurological deficit lasting <24 hours), 
- minor stroke (focal neurological deficit lasting >24 hours) or  
- amaurosis fugax (transient uniocular visual loss)  
presenting within 14 days of symptoms associated with a 50-99% internal carotid 
artery (ICA) stenosis were approached prior to carotid endarterectomy. 
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All patients with 
- claudication symptoms undergoing femoral endarterectomy were 
approached 
 
Age and sex matched controls were recruited from a cohort of patients presenting 
to clinic with varicose veins with normal Ankle Brachial Pressure Index (ABPI) 
and no evidence of significant carotid stenosis for plasma and urine assessment. 
These patients had a focused carotid duplex to exclude >50% ICA stenosis. 
 
2.2.1.2 Exclusion criteria 
- CT evidence of cerebral haemorrhage or lacunar infarcts as the cause for 
their cerebral events 
- Potential cardioembolic source for patient symptoms (cardiac arrhythmia 
on ECG or 24hr Holter monitoring; atrial thrombus or septal defect on 
echocardiography) 
 
2.2.2 Blood sample collection 
Blood samples were collected and prepared as described by Turner and 
colleagues (Turner, et al., 2008). 
- 20 ml venous blood samples were taken from the antecubital fossa after 
fasting for a minimum of 6 hours, using a 21 G butterfly needle and a “no-
tourniquet” technique to reduce cell crushing which may influence the 
results 
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- Blood samples were then put in lithium heparinised 4 ml tubes for the NMR 
study. There were two tubes from each patient 
- A further 3 blood samples were put in a 4 ml EDTA tube, 4 ml citrate tube 
and a 4 ml Gel clot active tube (for serum samples) respectively. These 
were not used in this study but kept for future research (figure 9) 
- All samples were centrifuged (eppendporf FBS29112 Centrifuge 5810 R) 
at 900 g for 10 mins within two hours of collection. Samples were kept in 
4oC until processing 
- Previous protein profiling studies suggested that plasma samples are 
more stable than serum ones, although the evidence is insufficient. Ideally 
both should be used, however this would complicate data analysis and the 
length of each experiment (Luque-Garcia & Neubert, 2007) and we 
therefore preceded with plasma analysis alone 
- Plasma   for the NMR study was taken from samples collected in LH tubes, 
divided into 400μl aliquots in Eppendorf tubes, (1.5 ml micro tubes; 
Sarstedt; Leicester, UK, Ref: 72.690), flash frozen in liquid nitrogen and 
stored in a freezer at −80°C ready for analysis 
- Centrifuging 8 ml of blood produces around 4-5 ml plasma. Each aliquot 
has 400 µl of plasma resulting in 10-12 samples from each patient 
- Plasma was taken from samples collected in EDTA and citrate tubes, 
divided into 100-150 μl aliquots in Eppendorf tubes, (1.5 ml micro tubes; 
Sarstedt; Leicester, UK, Ref: 72.690), flash frozen in liquid nitrogen and 
stored in a freezer at −80°C ready for analysis 
- Serum was taken from samples collected in Gel clot active tubes, divided 
into 100-150 μl aliquots in Eppendorf tubes, (1.5 ml micro tubes; Sarstedt; 
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Leicester, UK, Ref: 72.690), flash frozen in liquid nitrogen and stored in a 
freezer at −80°C ready for analysis 
- Centrifuging 4 ml of blood produces around 2-2.5 ml of plasma and serum. 
Each aliquot will have 100-150 µl of plasma and serum resulting in 10-12 
samples from each patient 
- Red blood cells (RBCs) (pellet) were also isolated from the samples, 
divided into 0.5 ml aliquots in Eppendorf tubes (1.5 ml micro tubes; 
Sarstedt; Leicester, UK, Ref: 72.690), flash frozen in liquid nitrogen and 
stored at −80°C until required for further studies 
 
 
Figure 9: Blood sample collection from patients 
 
2.2.2.1 Problems faced while processing blood samples 
Initially all samples were placed at 4oC prior to processing. However, when 
placing Gel clot active tubes at 4oC immediately after collection, only a small 
amount of serum was obtainable. This was due to the inability of the clotting 
factors in the sample to function at 4oC. Therefore, it was not possible to separate 
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the clotted RBCs from serum.  As advised by the literature, samples collected in 
Gel clot active tubes were left at room temperature for 15-20 mins before being 
placed at 4oC pending processing (Luque-Garcia & Neubert, 2007). 
 
2.2.3 Urine sample collection 
Urine samples were collected and prepared as described by Beckonert and 
colleagues (Beckonert, et al., 2007). 
- 20 ml of mid-stream morning urine sample was collected into sterile tubes 
containing 15 mM of boric acid 
- Sample was placed at 4oC pending processing 
- All samples were centrifuged (eppendporf FBS29112 Centrifuge 5810 R) at 
900g for 10 minutes at 4°C within two hours of collection 
- Supernatant was divided into 1.5 ml aliquots in Eppendorf tubes (1.5 ml 
micro tubes; Sarstedt; Leicester, UK, Ref: 72.690), flash frozen in liquid 
nitrogen and stored in a freezer at −80°C until required for analysis. 
- Each sample resulted in 14 aliquots 
 
2.2.4 Plaque samples protocol 
Protocol was initially drafted recommending the use of a modified surgical 
technique for carotid endarterectomy to the standard one allowing removal of 
intact plaque sample (Wijeyaratne, et al., 2002). However, changed provision of 
carotid endarterectomy meant that urgent surgery was shared amongst 
consultants, therefore loss of control on quality of samples received. 
 
75 
 
 
Femoral endarterectomy was carried out using a standard technique with 
maximum effort to remove intact plaques similar to the carotid ones. 
- Fresh plaque samples were processed within 30 minutes of excision 
- Recommendations made by Lovett and colleagues were considered for 
the preparation of the plaques for histological assessment (Lovett, et al., 
2005) 
- Transverse sections were taken from each plaque, using a scalpel blade 
at 1.5-2 mm intervals proximally to distally (common carotid to 
internal/external carotid) (figure 10) 
- Sections were labelled alphabetically in sequence. Alternate sections were 
either snap-frozen in liquid nitrogen then stored at -80 C for NMR studies, 
or kept in 4% paraformaldehyde (PFA) for histological studies (figure 11) 
- Each plaque was divided into 7-15 sections on average 
 
 
Figure 10: Plaque sections at 2 mm intervals 
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Figure 31: Plaque sectioning and processing 
Samples A – C – E – G – I – K were flash frozen in liquid nitrogen and stored in -80oC 
for NMR studies 
Samples B – D – F – H – J were kept in 4% paraformaldehyde for histological studies 
 
2.2.4.1 Histological methods 
Sections kept in 4% PFA were decalcified prior to embedding in paraffin. 
 
2.2.4.1.1 (4%) PFA preparation 
This was done by adding equal volumes of 8% PFA and 0.2 M Phosphate buffer 
(pH=7.4) solutions. 
 
2.2.4.1.1.1 (0.2) M Phosphate Buffer (pH=7.4) preparation 
Add 39.2 ml of KH2PO4 (1 M) to 160.8 ml of Na2HPO4 (1 M). Make up to 1 L by 
adding distilled water. Measure the pH and adjust by using HCl/NaOH to achieve 
pH of 7.4. 
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2.2.4.1.1.2 (8%) PFA preparation  
Add 80 g PFA powder to just under 500 ml of distilled water heated at 55oC. Spin 
the solution at 55oC until transparent. Add NaOH as appropriate (in drips) to fully 
clear. Top up the solution to 1 L with distilled water. 
 
2.2.4.1.2 Decalcification Protocol 
Initially, decalcification was attempted using Ethylene-Diamine-Tetra Acetic Acid 
(EDTA). Protocol for EDTA preparation was as follow: 
- EDTA (free acid) powder (Fisher Scientific UK Ltd) was used 
- 0.1 M phosphate buffer (pH=7.1) was prepared by adding 71.5 g of 
Na2HPO4 and 28.5 g of KH2PO4 to 1 L of DH2O 
- 10 g of EDTA powder was added to 100 ml of 0.1 M phosphate buffer 
- The mixture was stirred for 30 mins at least at 50oC 
 
However, there were two issues with this method: 
1- It was not possible to dissolve EDTA powder despite using different 
methods from the literature as well as local advice from Leeds Teaching 
Hospitals Labs. Experiment carried out with and without warming up. 
Adding NaHO (Buffer effect) was trialled with and without warming up. 
Prolonged stirred (Up to 3 days) was also endeavoured 
2- EDTA decalcification has not been used commonly in recent years due to 
its time-consuming disadvantage compared to formic acid (Prasad & 
Donoghue, 2013) 
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The decalcification protocol was changed, and formic acid was used as an 
alternative. Both EDTA and formic acid have good tissue preservation and 
staining efficacy regardless of the method used (Sangeetha, et al., 2013). 
Formic acid decalcification protocol was adapted from Leeds Teaching Hospitals 
Histopathology Labs. 
- Formic Acid 85% GPC (Atom Scientific) was used to prepare 8.5% by 
diluting in distilled H2O (1:9 volume) 
- Sample was placed in 8.5% Formic acid and left for 24 hrs 
- Chemical end-point test was used at 24 hours and every 12 hours 
thereafter, until sample was fully decalcified 
 
2.2.4.1.3 Chemical end-point test 
- 10-15 drops of concentrated ammonia were added to 5 ml of 8.5% formic 
acid until litmus paper changed colour to blue (alkali-tic) 
- 5 mg ammonium oxalate was diluted in 100 ml distilled H2O, and 9 ml of it 
was added to the previously made solution 
- The mixture was left for at least 30 mins then compared to a control formic 
acid sample 
- If clear the decalcification was done. Plaque was removed from Formic 
acid, rinsed with distilled water for a few mins and placed back in 4% PFA 
ready for paraffin embedding 
- If not clear after 30 mins, the formic acid used for decalcification was 
refreshed and the process was rechecked every 12 hours until clear 
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2.2.4.1.4 Paraffin embedding protocol 
Embedding was carried out using the embedding facility (Leica TP1020) in the 
LICAMM building at University of Leeds School of Medicine. All samples were 
treated by the same method. 
Steps for embedding were as follow: 
- Check if the 1st 70% alcohol container is clear. If not clear, fill the container 
with 500-600 ml 70% ethanol (EP, BP, 69.5-70.4%, Sigma-Aldrich 
Company Ltd, Poole, Dorset, UK) 
- Place sample in a tissue processing cassette (VMR biopsy cassettes – 
VMR Internationals, Catalogue No: 720-0290) 
- Place cassette in metal sieve 
- Raise the embedding machine lid: press button [↑] 
- Attach sieve to 1st lid (1st 70% ethanol) 
- Select program 3 “used by Dr Yuldasheva research group at LICAMM for 
embedding”. Make a note of the program used & the time expected to 
finish (Programme 3 takes 17 hours). When finished, raise the lid, take 
your samples out and lower the lid again 
- Switch on the wax temperature at 65oC one hour before starting 
embedding 
- Use a labelled plastic wax-holder to store the samples 
- Use metal moulds to place samples in melted paraffin then wait until 
cooled to be ready for sectioning 
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2.2.4.1.5 Processing paraffin blocks 
Paraffin blocks were kept at 4oC until sectioning time. 
- Each paraffin block was sectioned at 3-5 µm thickness based on 
calcification (More calcified samples were harder to section at 3 µm so 
went up to 4 or 5 µm). Occasionally a thicker section (6-8 µm) was taken 
if there was concern regarding section integrity with thinner, more fragile 
sections 
- All cut sections were then mounted on Polysine glass slides (TWIN 
Frosted Slides. Catalogue No: MAE-1000-03P. Cell Path) for greater 
adhesion properties compared to traditional glass slides 
- To further enhance adhesion property, Polysine slides were treated with 
3-aminopropyl-triethoxysilane (APES). This was done by placing the slides 
in 2% APES in Acetone (10 mins), distilled water (10 mins) then allowing 
slides to air dry  
- Sections were ready for haematoxylin and eosin (H&E) staining prior to 
analysis 
 
2.3 1H-NMR spectroscopy methods – liquid status 
 
2.3.1 Sample preparation 
Formerly described 1H-NMR spectroscopy methods for plasma and urine sample 
processing and analysis by Turner and colleagues, and Hopton and colleagues 
were used in this study (Turner, et al., 2008) (Hopton, et al., 2010). 
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All samples were left in the NMR spectrometer for 5 minutes to allow temperature 
equilibration before optimisation of parameters. 5 mm Norell NMR tubes (S-5-
500-7, GPE Scientific Ltd, Leighton Buzzard, Bedfordshire, UK) were used for 
placing samples in the NMR spectroscopy. All Samples (kept in -80oC) were 
thawed defrosted by warmth of hand. Samples were then centrifuged (Hettich 
Mikro 120 (C1204) Centrifuge, angle rotor A1242) at 11992 g for 5 min in room 
temperature. 
 
2.3.1.1 Plasma samples 
350 μl of deuterium oxide D2O (Sigma-Aldrich Company Ltd, Poole, Dorset, UK) 
was added to 300 μl of plasma in Eppendorf tube (1.5 ml micro tubes; Sarstedt; 
Leicester, UK, Ref: 72.690). For animal plasma samples, this was adjusted to 
370 μl of D2O and 250 μl of plasma due to the smaller volumes of the samples 
obtained. The plasma/ D2O mixture was vortexed for 5 seconds before 
transferring 600 μl of it to a 5 mm Norell NMR tube ready for analysis. Samples 
were kept at 4oC for a maximum of 30 min until placed in the NMR spectroscopy. 
 
2.3.1.2 Urine samples 
460 μl of urine in an Eppendorf tube (1.5 ml micro tubes; Sarstedt; Leicester, 
UK, Ref: 72.690) was added to 230μl of phosphate buffer (0.2 M phosphate 
buffer solution made up in water).  100 ml of phosphate buffer solution 
(pH=7.43) contained 2.885g sodium phosphate monobasic (Na2HPO4), 0.525g 
sodium phosphate dibasic, (NaH2PO4), 0.0172g (1 mM) trimethylsilyl propanoic 
acid (TSP) and 0.0195g (3mM) sodium azide (NaN3) in 20mL of D2O and 80ml
 
of ribonuclease (RNase) free water. The urine/phosphate buffer mixture was 
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vortexed for 5s before transferring 600 μl of it to a 5 mm Norell NMR tube ready 
for analysis. Samples kept at 4oC for a maximum of 30 min until placed in the 
NMR spectroscope. 
 
2.3.2 1H-NMR spectroscopy data collection 
1H-NMR spectra were then measured at a frequency of 499.97 MHz and a 
temperature of 20°C on a Varian Unity Inova 500 1H-NMR spectrometer (Varian 
Inc., Palo Alto, California, USA). All Spectra were saved as a free induction decay 
(FID) file ready for analysis. 
 
The Carr-Purcell-Meiboom-Gill (CPMG) spin-echo pulse sequence [RD – 90o – 
(τ – 180o – τ)n – acq] was used to suppress signals from macromolecules and other 
substances with short T2 values and obtain metabolic profiles for all plasma 
samples. The relaxation delay (RD) was 2 s, during which water resonance was 
selectively saturated. For each spectrum, 512 transients were collected into 
32,768 pairs of data points with a spectral width of 8,000.00 Hz. 
 
Diffusion-Ordered Spectroscopy (DOSY) pulse sequence was also used for 
macromolecules for all plasma samples. For each spectrum, 512 transients were 
collected into 32,768 pairs of data points with a spectral width of 8,000.00 Hz. 
The 1D NOESY (one-dimensional Nuclear Overhauser Effect Spectroscopy) 
pulse sequence [RD – 90o – t1 – 90o – tm – 90o – acq] was used to obtain 
metabolic profiles for all urine samples. The RD was 2 s, tm was 1.5 ms and t1 
was 3 µs. For each spectrum, 512 transients were collected into 16,384 pairs of 
data points with a spectral width of 8,000.00 Hz. 
83 
 
 
2.4 1H-NMR spectrometry methods - solid status 
High Resolution Magic Angle Spectrometry NMR (HR-MAS NMR) has been 
increasingly used for analysing solid tissues due to the advantage of studying 
intact tissues and the quality of signals obtained compared to other NMR based 
technologies. This facility was not available at Leeds University. Therefore, 
collaboration with the Birmingham University Henry Wellcome Building for 
Biomolecular NMR (HWB-NMR) Spectroscopy Unit was established and this part 
of the study was carried out there. The protocol for 1H-NMR spectrometry solid 
status analysis in this study was adapted from Beckonert and colleagues’ protocol 
(Beckonert, et al., 2010), and local protocols used at Birmingham University 
HWB-NMR unit. 
 
2.4.1 Sample preparation 
Preparation of tissue samples was done manually. 
- All Samples (kept in -80oC) were thawed at 4oC (ice) for 3-5 minutes 
- Samples were positioned in a 12 µl rotor, with 4 µl of D2O added to each 
sample as a solvent, and sealed with a rotor cap 
- The rotor was then inserted into the HR-MAS NMR spectroscope 
- Disposable rotor inserts were used to allow safe and contained handling 
of tissue in the NMR probe and quick replacement of samples from the 
rotors 
- The sample was kept at 4oC throughout the preparation 
- At the end of the process samples were removed from the NMR 
spectrometer, retrieved carefully and placed in Eppendorfs. Samples 
were then flash frozen in liquid nitrogen again and kept at -80oC 
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2.4.2 HR-MAS NMR spectroscopy 
A Bruker 500 MHz HR-MAS NMR spectrometer was used for this study. We relied 
on 1H nuclei because of the high natural abundance and hence short acquisition 
time (Garrod, et al., 1999). All Spectra were saved as a free induction decay (FID) 
file ready for analysis. 
 
Parameters of experiment: 
- Temperature: 4oC 
- Number of scans: 128 
- Spinning rate: 4800 Hz 
- (P12 = 3 mins, SP1 = 44.277, PL9 = 52, P2 = 9.5) 
 
Spectra achieved using the standard 1D NOESY proton NMR sequence were 
very weak in the pilot experiment, therefore the Carr–Purcell–Meiboom–Gill 
(CPMG) sequence was used in addition, to achieve stronger signals. 
This pulse sequence can be used to enhance only the contributions from 
macromolecules or to selectively highlight the signals from the fraction of small 
molecules without being invasive to the sample integrity in any way (Beckonert, 
et al., 2007) (Wang, et al., 2003). 
 
2.5 Spectral processing 
Protocol for processing and analysing of the acquired spectra was adapted from 
previous protocols by Turner and colleagues, and Hopton and colleagues  
(Turner, et al., 2008) (Hopton, et al., 2010). This was also the Standard Operating 
Procedure in the NMR lab at University of Leeds School of Chemistry. 
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- An exponential line broadening of 0.5 Hz was applied to each free 
induction decay (FID), before zero filling to 65,536 points, followed by 
Fourier transformation 
- The resultant spectra were phased, baseline corrected and referenced (α-
glucose at 5.24 ppm), using ACD Labs (NMR processor academic edition) 
software 12.01 (Advanced Chemistry Development, Inc., (ACD/Labs), 
Toronto, Canada) 
- The spectra were then “binned” into 225 segments, each with a width of 
0.04 ppm, over the range δ 0 to 10, setting δ 4.8 to zero, to suppress the 
water peak 
- Spectra was normalised to the unit sum of the spectral integral of the whole 
region examined, to ensure that the spectra were directly comparable 
- Prior to binning several dark regions were created to exclude signals from 
the water region and contaminants that may affect subsequent multivariant 
analysis. Those dark regions are summarised in table 7 
Sample Dark region Ppm 
Plasma (CPMG 
sequence) 
Highfield -3.2 → 0.8 
Water 4.68 → 5.2 
Aromatic 5.28 → 13 
Plasma (DOSY 
sequence) 
Highfield -1.5 → 0.6 
Water 4.4 → 5.0 
Aromatic 5.4 → 11 
Solid tissue (CPMG 
sequence) 
Highfield -3.2 → 0.8 
Water 4.6 → 5.16 
Aromatic 5.8 → 13.2 
Solid tissue (1D 
NOESY sequence) 
Highfield -3.2 → 0.5 
Water 4.6 → 5.16 
Aromatic 5.8 → 13.2 
Table 7: Dark regions excluded from spectra prior to binning and normalisation 
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2.6 Statistical analysis 
 
2.6.1 Multivariate statistical analysis (MVA) 
MVA has the ability to analyse many associated variables at the same time 
(Manly, 2005). Besides the standard chemometric techniques such as; principal 
components analysis (PCA) and partial least squares–discriminant analysis 
(PLS-DA), other multivariate analysis tools were used for the identification of 
metabolite signals that allow discrimination between the groups. Example of this 
is orthogonal partial least squares discriminant analysis (OPLS-DA). All 
multivariate statistical analyses were performed using SIMCA-P+ software 
version 14.1 (Umetrics, Umea, Sweden). 
 
The quality of these analyses was evaluated by validation metrics R2 and Q2. 
R2 reflects the relevance of information in the data set, while Q2 is an estimate of 
the predictive ability of the model. A value of more than 0.5 for both is usually 
desirable. In general, R2 should not exceed Q2 by more than 3 units. 
The chemical shifts of interest were analysed and linked to the correlating 
metabolite based on the chemical shift table published by Nicholson and 
colleagues (Nicholson, et al., 1995). 
 
2.6.1.1 PCA 
Principle component analysis (PCA) models were used to establish whether 
variables within the data can be differentiated into subgroups. This was 
demonstrated using scores plot which shows the correlation between 
observations. Loadings plot, which shows the correlation between variables, was 
then used to recognise the responsible bins for this differentiation. 
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2.6.1.2 PLS-DA and OPLS-DA 
These models were used to further distinguish between the differentiated groups 
and create prediction models for other groups. Score plots were used to 
demonstrate this, while w* loading plots were used to recognise the responsible 
bins for this differentiation. The results were then cross-validated by running the 
analysis 4 times after subtracting 1st, 2nd, 3rd, and 4th quarters from the data 
respectively. 
 
2.6.2 Univariate statistical analysis 
This was used to study the statistical significance of results resulting from the 
multivariate analysis.  Student’s t-test and Welch-Aspin test were used for normal 
data, based on whether the two groups have equal variances or not respectively. 
Fisher and Chi-square tests were used for categorical data. Mann-Whitney U test 
was used for non-parametric data. P-values were obtained to determine whether 
any difference between groups is statistically significant or not. The cut-off for 
significance used in this study was 0.05. All tests where done in IBM SPSS 
Statistics 25.0 software (IBM Corporation, New York, USA). 
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Chapter 3: NMR analysis of plasma 
Animal samples 
 
This chapter will describe 1H-NMR spectroscopy analysis of plasma obtained 
from 8 mice (3 ApoE-/- vs 5 control) using CPMG and DOSY pulse sequences. 
Samples were prepared as per Section 2.1.1 and 2.3.1.1. Data were collected as 
explained in Section 2.3.2. Spectra processing was done as per Section 2.5. 
Statistical analysis was done as per Section 2.6. 
 
Each mouse was given a number followed by a letter for identification purpose. 
The number was given to each animal according to the animal order of purchase 
in the University of Leeds Labs. The letter was either X for the study group or C 
for the control group. All the mice were born on 19th October 2011 and 
terminalised on 13th March 2012 (21-week-old). 
 
3.1 Results 
All animals were weighed immediately prior to terminalisation. There is a 
statistically significant difference between the two groups which may influence 
the following results from the NMR analysis. Table 8 details each animal weight 
in each group. 
 
Study Weight (g) Control Weight (g) P-value (t-test) 
18X 28.5 35C 36.4  
20X 33.6 36C 37.6  
21X 27 37C 38.6  
  38C 41.8  
  39C 45.5  
Mean ± SD 29.7 ± 3.46 Mean ± SD 39.98 ± 3.68 0.008 
Table 8: Mice weight: comparison between the study and control groups 
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3.1.1 Analysis of all mice plasma spectra – CPMG sequence 
 
3.1.1.1 PCA model 
A PCA model was produced for all the spectra obtained from mice plasma using 
CPMG sequence. Examples of the NMR spectra are shown in figure 12. A Very 
weak model with only 2 components detected. The goodness of fit R2X(cum) was 
0.489. The predictive ability Q2X(cum) was -0.0975. The negative value of 
Q2X(cum) indicates that this model is not predictive (figure 13). 
 
 
Figure 12: All mice plasma spectra with highlighted dark regions using CPMG sequence. 
X = chemical shifts (ppm), Y = Absolute intensity. 
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Figure 13: PCA model – All mice plasma – CPMG sequence 
 
Analysing the score scatter, it was obvious that the mice could not be clearly 
separated based on their metabolites (figure 14). Sample 37C was an outlier from 
the other control samples which were clustered otherwise, although it was not 
located outside of Hotelling’s T2 (which defines the normal area resembling the 
extent of which is bound by the ellipse with 95% confidence) (Eriksson, et al., 
2006). 37C behaviour could be another reason for the weakness of this model 
and the inability of samples separation. 
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Figure 14: Score scatter of the PCA model – All mice plasma – CPMG 
 
This was further established by looking at the score column (figure 15). 
 
Figure 45: Score column of the PCA model – All mice plasma – CPMG 
 
Removing sample 37C did not improve the model. The goodness of fit R2X(cum) 
was 0.522. The predictive ability Q2X(cum) was -0.11. However, it made the 
discrimination between study and control samples visible on the score scatter, 
without affecting the clustering pattern of the study group compared to the control 
group (figure 16). 
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Figure 16: Score scatter of the PCA model – All mice plasma (without sample 37C) – 
CPMG 
 
3.1.1.2 PLS-DA model 
A PLS-DA model was produced, and this was a much stronger model than the 
PCA with only 2 components detected. The goodness of fit R2X(cum) was 0.389 
and R2Y(cum) was 0.996. The predictive ability Q2X(cum) was 0.612 (figure 17). 
The difference is less than 0.3 between R2X and Q2X which means that there is 
less likelihood that too much noise or outlying data have affected the model 
(Eriksson, et al., 2006). A Q2X(cum) value of more than 0.5 means that the model 
is considered to have a good predictability (Ali, et al., 2012). 
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Figure 17: PLS-DA model – All mice plasma – CPMG sequence 
 
The score scatter of this model showed a clear separation between study and 
control samples (figure 18), with the score column demonstrating the clustering 
of the samples when arranging the scores in ascending order (figure 19).  
 
 
Figure 18: Score scatter of PLS-DA model – All mice plasma – CPMG 
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Figure 19: Score column of the PLS-DA model – All mice plasma – CPMG 
 
The matching loading column plots for component 1 and 2 are shown in figures 
20 and 21 respectively. These enable the identification of the plasma metabolites 
which are responsible for the discrimination and clustering of the samples. Table 
9 summarises the chemical shifts (bins) that were responsible for differentiating 
the two groups, and their correlating plasma metabolites responsible for the high 
scores (95% Confidence Intervals)  (Nicholson, et al., 1995).  
 
Bins in the range 0.98-1.06 ppm have a doublet spectral signal are consistent 
with valine (α-amino acid used in proteins biosynthesis). This was stronger in the 
study group alongside other protein biosynthetic α-amino acids, such as arginine 
(3.22 ppm - triplet) and alanine (3.78 ppm - quartet). Although, a doublet valine 
signal at 3.58 ppm and singlet glutamine (α-amino acid used in proteins 
biosynthesis) signal at 2.42 ppm were also present in component 2 of the loading 
plot. On the other hand, 2-oxoglutarate (2.46 ppm - triplet), which is a ketone 
derivative of glutaric acid, was stronger in the control group. Another strong signal 
in the control group was taurine (3.26 ppm - triplet) which is 2-
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aminoethanesulfonic acid which is a main ingredient of bile and can be found in 
the colon. 
3-hydroxybutyrate (2.38 ppm - singlet) was stronger in the study group. It is 
usually associated with ketosis, a metabolic state in which the body gains energy 
from ketone bodies instead of glucose. 
 
 
Figure 20: Component 1 loading column of the PLS-DA model – All mice plasma – 
CPMG 
 
 
Figure 21: Component 2 loading column of the PLS-DA model – All mice plasma – 
CPMG 
 
96 
 
 
 
 
 
 
Component 1 Component 2 
Bin 
Signal 
multiplicity 
Molecule Bin 
Signal 
multiplicity 
Molecule 
Study 
0.9 m Lipid 3.38 none  
0.98 d Valine 3.74 d αGlucose 
1.02 d Valine 3.9 d βGlucose 
1.06 d Valine    
1.38 d Lactate    
1.7 none     
1.74 none     
2.38 s 
3-
hydroxybutyrate 
   
3.9 d βGlucose    
Control 
0.86 t 
Lipid mainly 
LDL 
2.42 s Glutamine 
3.22 t Arginine 2.46 t 
2-
oxoglutarate 
3.26 t Taurine 2.5 none  
3.78 q Alanine 3.58 d Valine 
4.38 none  4.1 q Lactate 
Table 9 Chemical shifts responsible for high scores and correlating metabolites 
PLS-DA – All mice plasma – CPMG (s=singlet, d=doublet, t=triplet, q=quartet, 
m=complex multiplet) 
 
3.1.2 Analysis of all mice plasma spectra – DOSY sequence 
 
3.1.2.1 PCA model 
A PCA model was produced for all the spectra obtained from mice plasma using 
DOSY sequence. Examples of the NMR spectra are shown in figure 22. This was 
still a weak model with only 2 components detected. The goodness of fit 
R2X(cum) was 0.639. The predictive ability Q2(cum) was 0.231 (figure 23). The 
difference was more than 0.3 between R2X and Q2 which means that there was 
more likelihood that too much noise or outlying data was affecting the signals. 
Analysing the score scatter of this model, the two groups were discriminated 
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based on their metabolites with no apparent definite outliers (figure 24). Sample 
C37 still had the tendency to be separated from the clustered control samples, 
although removing C37 again from the experiment did not alter the plasma 
metabolites causing this groups discrimination. 
 
 
Figure 22: All mice plasma spectra with highlighted dark regions using DOSY 
sequence. X = chemical shifts (ppm), Y = Absolute intensity. 
 
 
 
Figure 23: PCA model – All mice plasma – DOSY sequence 
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Figure 24: Score scatter of the PCA model – All mice plasma – DOSY 
 
The matching loading column plot for this model produced more than 35 signals 
potentially causing the discrimination (figure 25). This suggests a probable noise 
effect which might have influenced the results, and it also makes identifying 
plasma metabolites which are responsible for samples discrimination more 
uncertain. Table 10 summarises the chemical shifts (bins) from strongest to 
weakest that could be responsible for differentiating the two groups, and their 
correlating plasma metabolites responsible for the high scores (95% Confidence 
Intervals)  (Nicholson, et al., 1995). 
 
It is apparent from the table of chemical shifts in this model that lipid metabolites 
have stronger signals in the study group, with mainly cholesterol and VLDL (very 
low-density lipoprotein) affecting their behaviour within the magnetic field.  Bins 
in the range 2.14-2.18 ppm have a complex multiplet spectral signal are 
consistent with glutamate. Glutamate is considered the richest free amino acid in 
brain. It is a neurotransmitter which plays an important role during brain growth 
and learning and memory development (Tapiero, et al., 2002). 
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The control group however had stronger signals of amino acids predominantly. 
Although, some of the signals were overlapping which made it difficult to establish 
which amino acid is causing the shift. Bins in the range 3.14-3.18 ppm have a 
doublet spectral signal are consistent with tyrosine or histidine. While bins in the 
range 3.58-3.62 ppm have doublet spectral signals are consistent with valine or 
threonine. Aspartate (2.62-2.66 ppm - doublet) is another α-amino acid with a 
stronger signal in the control samples. 
 
 
Figure 25: Loading column of the PCA model – All mice plasma – DOSY 
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Study Control 
Bin 
Signal 
multiplicity 
Molecule Bin 
Signal 
multiplicity 
Molecule 
1.22 m Lipid 1.14 none  
1.26 m Lipid 3.14 d 
Tyrosine 
Histidine 
0.82 m Cholesterol 1.18 none  
1.3 m Lipid 0.74 none  
1.98 m Lipid 2.66 d Aspartate 
1.5 m 
Lipid mainly 
VLDL 
0.78 m Cholesterol 
1.34 none  1.9 m 
Lysine 
Arginine 
2.18 m Glutamate 5.18 m 
Glyceryl of 
lipid 
2.46 none  3.58 d 
Valine 
Threonine 
1.54 m 
Lipid mainly 
VLDL 
3.62 d 
Valine 
Threonine 
2.14 m Glutamate 5.22 m 
Glyceryl of 
lipid 
1.38 none  2.7 m Lipid 
5.06 none  2.62 d Aspartate 
0.86 t 
Lipid mainly 
VLDL 
3.18 d 
Tyrosine 
Histidine 
2.5 none  0.7 none  
2.22 none  3.1 none  
5.3 none  1.42 none  
2.02 m Glutamate 1.1 none  
   1.86 none  
   2.82 none  
   1.02 none  
Table 10: Chemical shifts responsible for high scores and correlating metabolites. PCA 
– All mice plasma – DOSY  
(s=singlet, d=doublet, t=triplet, q=quartet, m=complex multiplet) 
 
3.1.2.2 PLS-DA and OPLS-DA model 
A PLS-DA model of this experiment did not add any further information. The 
model stayed weak with only one component detected. Although, the goodness 
of fit R2X(cum) improved to 0.412 with a much higher predictive ability Q2(cum) 
at 0.921. The difference in values between R2 and Q2 strongly suggested that 
the signals were affected by noise throughout the experiment. Figure 26 shows 
the score scatter of this model which again demonstrates group separation. 
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Figure 26: Score scatter of the PLS-DA model – All mice plasma – DOSY 
 
Similarly, the OPLS-DA model did not add any further information, and the 
strength of the model did not improve with 3 more forced components detected 
that might be affecting group separation. It is suggested that if more than five 
PLS/OPLS components are included in the model the training set data generally 
reproduce excellently (Ali, et al., 2012). 
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3.2 Discussion 
Animal plasma experiments in this study have shown weak results which were 
difficult to interpret, and it was not possible to generate a model that could 
confidently establish certain metabolites as atherosclerotic biomarkers.  
 
The effect of lipid signals on the study group was noticeable, although their strong 
signals might have covered other signals that could represent a significant 
biomarker. This was more obvious in the DOSY experiment, which is designed 
for detecting macromolecules. Unfortunately, this was not replicated in the CPMG 
experiment and with mixed results it was not possible to follow the metabolic 
pathways that might be responsible for group separation. Similar mixed results 
were witnessed regarding the effect of amino acids on both groups and therefore 
difficult to interpret. 
 
Interestingly, taurine signals were more evident in the control group. Taurine is 
thought to play an important role in supressing the development of 
atherosclerosis and has preventative influence on cardiovascular diseases and 
diabetes mellitus complications (Murakami, 2014) (Sarkar, et al., 2017). 
 
This study had a small number of mice (3 study v 5 control) compared to other 
studies conducted in the same field (Martin, et al., 2009) (Leo & Darrow, 2009) 
(Yang, et al., 2014). This could be another reason for the models’ weakness. 
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Chapter 4: NMR analysis of solid tissues 
Animal samples 
 
This chapter will describe High Resolution Magic Angle Spinning 1H-NMR 
spectroscopy analysis of aortic arches obtained from 10 mice (5 ApoE-/- vs 5 
control) using CPMG and 1D NOESY pulse sequences. Samples were prepared 
as per Section 2.1.2 and 2.4.1. Data were collected as explained in Section 2.4.2. 
Spectra processing was done as per Section 2.5. Statistical analysis was done 
as per Section 2.6. 
 
Each mouse was given a number followed by a letter for identification purpose. 
The number was given to each animal according to the animal order of purchase 
in the University of Leeds Labs. The letter was either X for the study group or C 
for the control group. All the mice were born on 19th October 2011 and 
terminalised on 13th March 2012 (21-week-old). 
 
4.1 Results 
All animals were weighed immediately prior to terminalisation. There is a 
statistically significant difference between the two groups which may influence 
the following results from the NMR analysis. Table 11 details each animal weight 
in each group. 
Study Weight (g) Control Weight (g) P-value (t-test) 
18X 28.5 35C 36.4  
19X 33.1 36C 37.6  
20X 33.6 37C 38.6  
21X 27 38C 41.8  
22X 39 39C 45.5  
Mean ± SD 32.24 ± 4.74 Mean ± SD 39.98 ± 3.68 0.0203 
Table 11: Mice weight: comparison between the study and control groups 
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4.1.1 Analysis of all mice solid tissues spectra – CPMG sequence 
 
4.1.1.1 PCA model 
A PCA model was produced for all the spectra obtained from mice aortic arches 
using CPMG sequence. Examples of the NMR spectra are shown in figure 27. A 
very weak model again was demonstrated and only 1 component was detected. 
The goodness of fit R2X(cum) was 0.442. The predictive ability Q2(cum) was -0.1. 
Similar to the animal plasma experiment, the negative value of Q2(cum) indicates 
that this model is not predictive (figure 28). 
 
 
Figure 27: All mice solid tissue spectra with highlighted dark regions using CPMG 
sequence. X = chemical shifts (ppm), Y = Absolute intensity. 
105 
 
 
 
Figure 28: PCA model – All mice solid tissue – CPMG sequence 
 
Analysing the scorer scatter and column, the mice could not be separated based 
on their metabolites. Sample 21X, however, seemed to have a stronger effect on 
the study group and could be therefore an outlier (figure 29). This could be one 
of the reasons for the weakness of this model and the inability of samples 
separation. 
 
Removing sample 21X did not improve the model. The goodness of fit R2X(cum) 
was 0.666. The predictive ability Q2(cum) was -0.0673. However, it did increase 
the number of detected components to 3, without affecting the clustering pattern 
of the study group compared to the control group or separating them (figure 30). 
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Figure 29: Score column of the PCA model – All mice solid tissue – CPMG 
 
 
Figure 30: Score scatter of the PCA model – All mice solid tissue (without sample 21X) 
– CPMG 
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4.1.1.2 PLS-DA and OPLS-DA models 
A PLS-DA model for this experiment was produced, and this was a stronger 
model than the PCA with only 1 component detected. The goodness of fit 
R2X(cum) was 0.399 and R2Y(cum) was 0.466. The predictive ability Q2(cum) 
was 0.221 (figure 31).  
 
Similarly, the OPLS-DA model did not add any further information, and the 
strength of the model did not improve without being able to force any further 
components that may affect group separation. 
 
On further analysis of the original spectra and the loading column of this model, 
there was one area of interest that had higher signals in the study group. This 
area matched bins in the range 3.54-3.58 ppm. The signal was a doublet which 
is consistent with valine (figure 32). 
 
 
Figure 31: PLS-DA model – All mice solid tissue – CPMG sequence 
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Figure 32: Valine signal - PLS-DA model – All mice solid tissue – CPMG sequence 
 
 
4.1.2 Analysis of all mice solid tissue spectra – 1D NOESY sequence 
 
4.1.2.1 PCA model 
A PCA model was produced for all the spectra obtained from mice aortic arches 
using 1D NOESY sequence. Examples of the NMR spectra are shown in figure 
33. This was a weak model with 3 components detected. The goodness of fit 
R2X(cum) was 0.708. The predictive ability Q2(cum) was -0.0357 (figure 34). The 
negative value of Q2(cum) indicates that this model is not predictive.  
 
It was noted, however, that the original spectra obtained using 1D NOESY 
sequence were easier to process, and produced sharper signals compared to the 
CPMG sequences. This was in contrast to what was experienced during the NMR 
analysis and spectra acquisition (section 2.4.2). 
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Figure 33: All mice solid tissue spectra with highlighted dark regions using 1D NOESY 
sequence. X = chemical shifts (ppm), Y = Absolute intensity. 
 
 
Figure 34: PCA model – All mice solid tissue – 1D NOESY sequence 
 
Analysing the score scatter of this model showed a very weak separation 
between the study and control samples (figure 35). The score column for this 
model did not demonstrate any clustering of the samples, when arranging the 
scores in ascending order (figure 36). 
 
110 
 
 
 
Figure 35: Score scatter of the PCA model – All mice solid tissue – 1D NOESY 
 
 
Figure 36: Score column of the PCA model – All mice solid tissue – 1D NOESY 
 
The loading column plot of this model did not reveal any additional information. 
The only two signals identified as potential contributors to the weak separation 
were at bins 1.12 ppm (isobutyrate) and 4.28 ppm (threonine). It was, however, 
not possible to determine how each of them affects both groups. 
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4.1.2.2 PLS-DA and OPLS-DA models 
A PLS-DA model for this experiment was produced, which was a stronger model 
than the PCA with only 1 component detected. The goodness of fit R2X(cum) was 
0.228 and R2Y(cum) was 0.778. The predictive ability Q2(cum) was 0.383 (figure 
37). A more apparent separation was observed in this model and samples were 
clearly clustering according to their relevant groups. Sample 35C was the only 
sample which behaved as an outlier, although it did not affect group separation 
as shown in the score scatter (figure 38).  
 
Similarly, the OPLS-DA model was stronger than the PCA with 1 component 
detected. This model did not add any further information to the experiment with 6 
more forced components detected that might be affecting group separation 
(figure 39). 
 
 
Figure 37: PLS-DA model – All mice solid tissue – 1D NOESY sequence 
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Figure 38: Score scatter of the PLS-DA model - All mice solid tissue - 1D NOESY 
 
Figure 39: OPLS-DA model – All mice solid tissue – 1D NOESY sequence 
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The matching loading column plot for this model produced 9 signals potentially 
causing the discrimination (figure 40). Table 12 summarises the chemical shifts 
(bins) from strongest to weakest that could be responsible for differentiating the 
two groups, and their correlating plasma metabolites responsible for the high 
scores (95% Confidence Intervals)  (Nicholson, et al., 1995). 
 
Bins in the range 0.96-1.00 ppm have a doublet spectral signal are consistent 
with leucine, valine or isoleucine. These were stronger in the study group, but it 
was difficult to determine which metabolite is causing the shift. This is mainly due 
to a large lipid signal covering that area of the spectra.  Taurine signal (3.28 ppm 
- triplet) was the dominant metabolite affecting the control group. The only other 
metabolite with an effect on the control group was acetate (1.88 ppm - singlet). 
 
 
Figure 40: Loading column of the PLS-DA model – All mice solid tissue – 1D NOESY 
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Study Control 
Bin Signal multiplicity Molecule Bin Signal multiplicity Molecule 
1.00 d 
Leucine 
Valine 
Isoleucine 
3.28 t Taurine 
0.96 d 
Leucine 
Valine 
Isoleucine 
1.4 none  
   2.8 none  
   4.56 none  
   4.52 none  
   4.6 none  
   1.88 s Acetate 
Table 12: Chemical shifts responsible for high scores and correlating metabolites. PLS-
DA - All mice solid tissue - 1D NOESY 
(s=singlet, d=doublet, t=triplet, q=quartet, m=complex multiplet) 
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4.2 Discussion 
Animal solid tissue experiments in this study have shown weak results which 
were difficult to interpret, and it was not possible to generate a model that could 
confidently establish certain metabolites as atherosclerotic biomarkers. 
Promising findings were observed, however, in the 1D NOESY sequence 
experiment. 
 
The effect of strong lipid signals on the spectra was noticeable and they might 
have covered other signals that could represent a significant biomarker. Perhaps 
the most interesting finding is the strong taurine signal which was present in mice 
plasma from the control group in the previous experiment (CPMG sequence), as 
well as the control mice aortic arch in this experiment (1D NOESY sequence). 
 
This study had a small number of mice (5 study v 5 control) which could explain 
the models’ weakness. Although, there are no other similar studies which use 
intact solid tissues in the NMR analysis for comparison.  
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Chapter 5: NMR analysis of plasma 
Human samples 
 
This chapter will describe 1H-NMR spectroscopy analysis of plasma obtained 
from 77 patients. Samples were prepared as per Section 2.3.1 and 2.3.1.1. Data 
were collected as explained in Section 2.3.2. Spectra processing was done as 
per Section 2.5. Statistical analysis was done as per Section 2.6. 
 
Each plasma sample was given a set of letters followed by a number for 
identification purpose. The letters were: (Ca) for patients with symptomatic carotid 
disease, (Fe) for patients with symptomatic femoral disease, and (Ctrl) for 
patients from the control group. The number given to each sample was according 
to their order of recruitment. 
 
5.1 Results 
Out of 83 patients recruited for this study, 2 from the control group did not attend 
their out-patient appointments, 1 from the femoral endarterectomy group was 
cancelled due to medical reasons, 2 patients withdrew from the study and I could 
not use their samples, and 1 patient from the femoral endarterectomy group went 
to theatre prior to me being able to take a blood sample for the study. 
 
77 plasma samples were analysed. Patients’ demographics, relevant past 
medical history and current medications are summarised in table 13. 
More detailed statistical analysis of patients’ data will be discussed throughout 
this chapter wherever found relevant. 
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 Carotid Femoral Control 
Number of patients 42 18 17 
Male/Female 27/15 15/3 8/9 
Age (years) 
Range 44-91 46-79 44-90 
Mean 70.7 ± 10.8 64.9 ± 10.2 67.6 ± 8.7 
Median 73 69 67 
BMI (kg.m-2) 
Range 20 – 43 16.8 - 39 22.4 – 50.2 
Mean 27.9 ± 4.5 26.8 ± 5.7 31.1 ± 8.6 
Median 28.5 26.5 30.8 
Smoke 
Current 15 9 3 
Ex 19 8 5 
Never 8 1 9 
Alcohol (unit) 
Range 0-75 0-65 0-90 
Mean 12.2 ± 12.9 18.3 ± 15.1 13.7 ± 20.8 
Median 10 15 10 
Hypertension 
Treated 23 11 6 
Untreated 3 2 2 
Diabetes Mellitus 
Diet 6 0 0 
Oral 5 1 1 
Insulin 2 1 0 
hyperlipidaemia 11 7 2 
Antiplatelet therapy 37 16 4 
Statins 38 15 8 
Table 13: Patients demographics and medical background – NMR plasma study 
 
5.1.1 Analysis of all human plasma spectra – CPMG sequence 
 
5.1.1.1 PCA model 
A PCA model was produced for all the spectra obtained from analysing human 
plasma using CPMG sequence. The goodness of fit R2X(cum) was 0.808. The 
predictive ability Q2(cum) was 0.269. The difference between R2X and Q2 
suggested that there were either too much noise or many outliers affecting the 
signals. In the initial run of data 13 components were detected, and the control 
group seemed to be different from the carotid and femoral groups. 
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Sample Ctrl-078 noted to have a large ethanol signal compared to the rest, which 
suggests a high alcohol consumption prior to sampling (figure 41). This patient 
reported an alcohol intake of around 90 units per week, which was the highest 
amongst all patients. Sample Ctrl-078 was considered to be therefore an outlier 
with a potential significant effect on the results, and it was removed from this 
analysis. 
A second PCA model was then produced, the goodness of fit R2X(cum) was 
0.822 and the predictive ability Q2(cum) was 0.302. 14 components were 
detected in this model (figure 42).  
 
 
Figure 41: ethanol signal in sample Ctrl-078 (plasma) 
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Figure 42: PCA model – All human plasma (without Ctrl-078) – CPMG sequence 
 
The score scatter of this model showed a degree of separation and clustering 
between the groups, although clustering patterns were noticed within each group 
as well (figure 43). 
 
 
Figure 43: Score scatter of the PCA model – All human plasma (without Ctrl-078) – 
CPMG 
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4 further outliers (Ca-010, Ca-011, Ca-015, Ctrl-065) could be identified in this 
scatter. Analysing each spectrum and correlating patient’s data, it was not 
possible to explain this behaviour. A third PCA model was then produced (figure 
44). Based on this third model, there was no obvious improvement in the 
separation or clustering patterns between the groups. Therefore, these outliers 
were kept in the experiment and were observed for similar behaviour in other 
models. 
 
 
Figure 44: Score scatter of the PCA model – All human plasma (without samples Ca-
010, Ca-011, Ca-015, Ctrl-065, Ctrl-078) – CPMG 
 
The second PCA model also suggested a slight separation based on patients’ 
gender (figure 45). However, there was a statistically significant difference in the 
number of males versus females in this study (49 v 27, P-value = 0.0116).  This 
was not further analysed at this stage, and further models may be built for each 
gender if this pattern continues to show throughout the experiment. 
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Figure 45: Score scatter of the PCA model based on gender – All human plasma 
(without Ctrl-078) – CPMG 
 
5.1.1.2 PLS-DA and OPLS-DA models 
A PLS-DA model was produced for all the spectra obtained from analysing human 
plasma using CPMG sequence. The goodness of fit R2X(cum) was 0.136 and 
R2Y(cum) was 0.177. The predictive ability Q2(cum) was 0.0472. Similar to the 
PCA model, sample Ctrl-078 had a high ethanol signal and was removed from 
the experiment. 
 
A second PLS-DA model was then produced excluding sample Ctrl-078. The 
goodness of fit R2X(cum) was 0.143 and R2Y(cum) was 0.17. The predictive 
ability Q2(cum) was 0.0604. This was a weaker model than the PCA with only 1 
component detected. There was however a clearer separation of the control 
group from the other two groups based on their metabolites (figure 46).  This 
model also suggested a sub-clustering behaviour within the femoral 
endarterectomy group. Analysing the relevant spectra and patients’ data, it was 
not possible to explain this behaviour within the magnetic field (figure 47). 
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Figure 46: Score scatter of the PLS-DA model - All human plasma (without Ctrl-078) – 
CPMG 
 
 
Figure 47: Score scatter of the PLS-DA model showing the sub-clustering of the 
femoral endarterectomy group – All human plasma (without Ctrl-078)– CPMG 
 
The OPLS-DA model forced 2 more components and further established the 
separation between the control and both the femoral and carotid endarterectomy 
groups. However, the sub-clustering of the femoral endarterectomy group 
became less apparent in this model, although it highlighted a slight separation 
between the femoral ad carotid endarterectomy groups (figure 48). 
123 
 
 
 
 
Figure 48: Score scatter of the OPLS-DA model – All human plasma (without Ctrl-078) 
– CPMG 
 
The matching score and loading column plots of these models produced 15 
signals potentially causing the discrimination between the control and 2 study 
groups (figures 49 and 50). Table 14 summarises the chemical shifts (bins) from 
strongest to weakest that could be responsible for differentiating the groups, and 
their correlating plasma metabolites responsible for the high scores (95% 
Confidence Intervals)  (Nicholson, et al., 1995). 
 
Bins in the range 3.02-3.05 ppm with a singlet spectral signal corresponds to 
either creatine or creatinine. These were found to be stronger in the control 
samples. Creatine is mainly produced in the liver and kidneys, and it helps in 
reprocessing of ATP (adenosine triphosphate) which plays an important role in 
the energy cycle in the body. Creatinine is a breakdown of creatine and is an 
important marker of the renal function clinically. Only two patients from the carotid 
endarterectomy group were known to have chronic kidney disease, according to 
its definition by the UK Renal Association (The Renal Association, 2017). This 
did not explain the stronger creatinine and creatine signals in the control group. 
124 
 
 
The control group had a stronger signal of the amino acid glutamate (2.18 ppm - 
complex multiplet), and the ketone derivative of glutaric acid 2-oxoglutarate (2.50 
ppm - triplet). Choline (3.18 ppm - singlet), which is a water-soluble vitamin-like, 
was noticed to be stronger in the control group as well. 
 
The study groups, on the other hand, were predominantly affected by strong 
glucose signals. Only one patient was diabetic in the control group compared to 
15 in the study groups (13 carotid + 2 femoral). This difference though was 
statistically not significant (P-value = 0.1673). Another factor was that all the 
patients in the study groups were fasting at the time of blood sampling. While only 
one patient from the control group was fasting. Those two factors may well 
explain the stronger glucose signals. However, adding those glucose signals to 
the dark regions did not add or alter the information gained from this model. 
Therefore, further analysis of diabetic versus non-diabetic samples was not 
carried out at this stage. 
 
Other signals affecting the study groups were taurine (3.26 ppm - triplet) and 
lactate (1.34 ppm - doublet). Lactate is usually increased when there is a higher 
demand for energy by tissues (exercise or hypo-perfusion for example). 
It was also noticed that bins in the range 0.85-0.93 ppm had a strong lipid signal 
in all samples. Some signals in this range might have been covered by the lipid 
signal and were not exposed by this model. 
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Figure 49: Score column of the PLS-DA model showing the clustering of control 
samples to the left when arranging the scores in ascending order 
All human plasma (without Ctrl-078) – CPMG 
 
 
Figure 50: Loading column of the PLS-DA model - All human plasma (without Ctrl-078) 
– CPMG 
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Study (carotid and femoral) Control 
Bin 
Signal 
multiplicity 
Molecule Bin Signal multiplicity Molecule 
1.34 d Lactate 3.02 s 
Creatine 
Creatinine 
3.26 t Taurine 2.18 m Glutamate 
3.5 dd β-glucose 3.18 s Choline 
3.46 dd β-glucose 2.98 none  
3.38 t β-glucose 4.66 d β-glucose 
3.42 t α-glucose 2.5 t 2-oxoglutarate 
1.3 none  4.34 none  
   1.74 none  
Table 14: Chemical shifts responsible for high scores and correlating metabolites. PLS-
DA - All human plasma (without Ctrl-078) – CPMG 
(s=singlet, d=doublet, dd=doublet of doublet, t=triplet, q=quartet, m=complex multiplet) 
 
5.1.2 Analysis of human plasma spectra (carotid v femoral) – CPMG 
sequence 
A PCA model was produced for all the spectra obtained from analysing human 
(carotid and femoral endarterectomy patients) plasma using CPMG sequence. 
The goodness of fit R2X(cum) was 0.777. The predictive ability Q2(cum) was 
0.264. The difference between R2X and Q2 suggested that there were either too 
much noise or many outliers affecting the signals. In the initial run of data 11 
components were detected, and there was no obvious separation between the 
carotid and femoral samples (figure 51). 
 
This finding was also repeated in the PLS-DA model with no component detected 
to suggest groups discrimination. An OPLS-DA model was then produced and 
only one forced component was detected. This was a very weak model with small 
R2 value and negative Q2 value (R2X = 0.103, R2Y = 0.302, Q2 = -0.0635). 
However, a slight degree of separation was noticed in this model. 
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Figure 51: Score scatter of the PCA model - (carotid v femoral) plasma - CPMG 
 
From figure 51, 5 outliers (Ca-010, Ca-011, Ca-012, Ca-015, Fe-049) could be 
identified in the score scatter of this PCA model. Analysing each spectrum and 
correlating patient’s data, it was not possible to explain this behaviour. Although 
it was noticed that plasma samples from the first 4 outliers were processed within 
a short period of each other. This did not however affect other samples processed 
around the same time. 
 
 A second PCA model was then produced excluding those outliers. 9 components 
were detected in this model (R2X = 0.715 and Q2 = 0.178). Based on this second 
model, there was a degree of separation and clustering between the two groups. 
Although the PLS-DA model did not strengthen this separation, the OPLS-DA 
model detected 2 forced components and it was certainly stronger (R2X = 0.199, 
R2Y = 0.526, Q2 = 0.0214). The separation between the two groups was more 
obvious too (figure 52). 
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Figure 52: Score scatter of the OPLS- DA model - (carotid v femoral) plasma -(without 
samples Ca-010, Ca-011, Ca-012, Ca-015, Fe-049) - CPMG 
 
Analysing the matching loading column plot, there were 6 signals affecting the 
carotid group that potentially could be causing the discrimination noted in the 
OPLS-DA model.  Bins in the range 4.22-4.34 have complex multiplet signals are 
consistent with either lipids or threonine. The carotid group had stronger signals 
at 4.22, 4.26, 4.3 and 4.22 ppm. Another stronger signal in the carotid group was 
noticed at 3.87 ppm (doublet of doublets) which is consistent with β-glucose. 
 
The only other signal which was stronger in the carotid group was at 1.5 ppm. 
This was a weak doublet signal and the closest metabolite to it was alanine. 
No dominant signals (with 95% confidence intervals) were observed in the 
femoral group in this model. 
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5.1.3 Analysis of all human plasma spectra – DOSY sequence 
 
5.1.3.1 PCA model 
A PCA model was produced for all the spectra obtained from analysing human 
plasma using DOSY sequence. A stronger model was observed compared to the 
CPMG sequence experiment. The goodness of fit R2X(cum) was 0.79 and the 
predictive ability Q2(cum) was 0.39. The difference between R2X and Q2 was still 
more than 0.3 and it suggested that there were either too much noise or many 
outliers affecting the signals. In the initial run of data 12 components were 
detected with no clear separation between the groups. 
 
Sample Ctrl-078 was again noted to have a large ethanol signal compared to the 
rest, which suggests a high alcohol consumption prior to sampling. Sample Ctrl-
078 was removed from this analysis. A second PCA model was then produced, 
the goodness of fit R2X(cum) was 0.721 and the predictive ability Q2(cum) was 
0.4. 9 components were detected in this model. The score scatter of this model 
did not show a clear separation of the groups, although some clustering patterns 
were observed (figure 53). 
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Figure 53: Score scatter of the PCA model - All human plasma (without Ctrl-078) – 
DOSY 
 
Only 1 outlier (Ctrl-065) could be identified in this scatter, which was also an 
outlier in the PCA model of the CPMG sequence experiment. Analysing the 
spectrum and correlating patient’s data did not explain this behaviour.  
A third PCA model was then produced excluding Ctrl-065. The goodness of fit 
R2X(cum) was 0.787 and the predictive ability Q2(cum) was 0.371. 12 
components were detected in this model with a slight separation between the 
groups noted on the score scatter (figure 54). 
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Figure 54: Score scatter of the PCA model - All human plasma (without Ctrl-078 and 
Ctrl-065) - DOSY 
 
5.1.3.2 PLS-DA and OPLS-DA models 
A PLS-DA model was produced for all the spectra obtained from analysing human 
plasma using DOSY sequence. This did not detect any components and an 
OPLS-DA model was then produced. This forced 2 components. The goodness 
of fit R2X(cum) was 0.429 and R2Y(cum) was 0.374. The predictive ability 
Q2(cum) was 0.0986. Similar to the PCA model, sample Ctrl-078 had a high 
ethanol signal and was removed from the experiment. 
 
A second PLS-DA model was then produced excluding sample Ctrl-078. This too 
did not detect any components and an OPLS-DA model was produced which also 
forced 2 components. The goodness of fit R2X(cum) was 0.429 and R2Y(cum) 
was 0.382. The predictive ability Q2(cum) was 0.112.  
 
A third PLS-DA model was produced excluding Ctrl-078, as this was still the only 
obvious outlier. This was a better model than the first two versions. only 1 
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component was detected, and a slightly clearer separation and clustering pattern 
was witnessed. The goodness of fit R2X(cum) was 0.165 and R2Y(cum) was 
0.179. The predictive ability Q2(cum) was 0.0475 (figure 55). 
 
 
Figure 55: Score scatter of the PLS-DA model - All human plasma (without Ctrl-078 
and Ctrl-065) - DOSY 
 
The companion OPLS-DA model did show similar results, with 2 forced 
components detected in a stronger model (R2X = 0.495, R2Y = 0.497, Q2 = 0.108). 
The separation between the two groups was more obvious too (figure 56). 
Observing the pattern of separation, it was evident that direct comparison 
between each two groups separately was more informative than all the three 
together. 
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Figure 56: Score scatter of the OPLS-DA model - All human plasma (without Ctrl-078 
and Ctrl-065) - DOSY 
 
5.1.4 Analysis of human plasma spectra (carotid v control) – DOSY 
sequence 
A PCA model was produced for all the spectra obtained from analysing human 
(carotid endarterectomy and control patients) plasma using DOSY sequence. 
The goodness of fit R2X(cum) was 0.766. The predictive ability Q2(cum) was 0.34. 
The difference between R2X and Q2 suggested that there were either too much 
noise or many outliers affecting the signals. 10 components were detected (figure 
57), and there was a degree of separation between the carotid and control 
samples.  
 
This separation was much clearer in the PLS-DA model which was subsequently 
produced (R2X = 0.321, R2Y = 0.639, Q2 = 0.339), with 2 components detected 
(figure 58). 
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Figure 57: PCA model – Human plasma (carotid v control) - DOSY 
 
 
Figure 58: Score scatter of the PLS-DA model - Human plasma (carotid v control) - 
DOSY 
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The matching loading column plots of this model produced 32 signals potentially 
causing the discrimination between the carotid endarterectomy and the control 
groups (figures 59). 
 
 
Figure 59: Loading column of the PLS-DA model – Human plasma (carotid v control) - 
DOSY 
 
Table 15 summarises the chemical shifts (bins) from strongest to weakest that 
could be responsible for differentiating the groups, and their correlating plasma 
metabolites responsible for the high scores (95% Confidence Intervals)  
(Nicholson, et al., 1995). 
 
It was noticeable from the table of chemical shifts in this model that lipid 
metabolites had stronger signals in the study group, with mainly LDL (low-density 
lipoprotein) and VLDL (very low-density lipoprotein) affecting their behaviour 
within the magnetic field. The only other two metabolites that were potentially 
affecting the study samples were 3-hydroxybutyrate (4.18 ppm - complex 
multiplet) and the amino acid isoleucine (1.94 ppm - complex multiplet). 
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The control group however had stronger signals of amino acids predominantly. 
Histidine (3.14 ppm - doublet) was the α-amino acid with the strongest effect on 
the control samples. Bins in the range 3.58-3.62 ppm have a doublet spectral 
signal are consistent with valine or threonine. Aspartate (2.62-2.66 ppm - doublet) 
is another α-amino acid with a stronger signal in the control samples. α-glucose 
was also stronger in the control group, although this could be due to the patients 
not being fasted ta the time of blood sampling. 
 
Study Control 
Bin 
Signal 
multiplicity 
Molecule Bin 
Signal 
multiplicity 
Molecule 
2.54 none  5.18 d α-glucose 
1.5 m 
Lipid (mainly 
VLDL) 
3.14 dd Histidine 
4.18 m 
3-
hydroxybutyrate 
2.26 none  
1.54 m 
Lipid (mainly 
VLDL) 
3.42 none  
1.94 m Isoleucine  0.74 m Cholesterol 
1.22 m 
Lipid (mainly 
LDL) 
3.38 none  
1.46 m 
Lipid (mainly 
VLDL) 
0.78 m Cholesterol 
2.58 none  2.22 none  
0.82 t 
Lipid (mainly 
LDL) 
5.14 d α-glucose 
2.42 none  1.14 none  
1.18 m Lipid 2.66 dd Aspartate 
1.58 m 
Lipid (mainly 
VLDL) 
3.62 d 
Valine 
Threonine 
3.98 none  2.86 none  
1.26 m Lipid 4.06 m 
Glyceryl of 
lipids 
3.06 none  3.58 d 
Valine 
Threonine 
   2.06 none  
   2.62 dd Aspartate 
Table 15: Chemical shifts responsible for high scores and correlating metabolites. PLS-
DA - Human plasma (carotid v control) – DOSY 
(s=singlet, d=doublet, dd=doublet of doublet, t=triplet, q=quartet, m=complex multiplet) 
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5.1.5 Analysis of human plasma spectra (carotid v femoral) – DOSY 
sequence 
A PCA model was produced for all the spectra obtained from analysing human 
(carotid and femoral endarterectomy patients) plasma using DOSY sequence. 
The goodness of fit R2X(cum) was 0.751. The predictive ability Q2(cum) was 
0.322. The difference between R2X and Q2 suggested that there were either too 
much noise or many outliers affecting the signals. 10 components were detected, 
and there was a slight separation between the carotid and control samples (figure 
60). 
 
This separation was not produced in the subsequent PLS-DA model, and no 
components were detected. The OPLS-DA model for this experiment did force 2 
components and a separation became more obvious between the two groups 
(figure 61). This was a weak model though, with R2X value of 0.284, R2Y value 
of 0.479, and a negative Q2 value of -0.0266. 
 
 
Figure 60: Score scatter of the PCA model - Human plasma (carotid v femoral) - DOSY 
 
138 
 
 
 
Figure 61: Score scatter of the OPLS-DA model - Human plasma (carotid v femoral) - 
DOSY 
 
Detailed analysis of the matching loading column plot did not reveal many signals 
that could have affected the two groups, with only three signals that were thought 
to be affecting the possible discrimination between them.  Histidine (3.14 ppm - 
doublet) was stronger in the femoral group. While a large lipid signal was primarily 
affecting the carotid samples (range 1.98-2.02 ppm - complex multiplet). 
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5.2 Discussion 
Human plasma (carotid, femoral and control) experiments in this study have 
shown mixed results, some were challenging to interpret, and it was difficult to 
generate a model that could confidently establish certain metabolites as 
atherosclerotic biomarkers. 
 
Similarity of some findings between these experiments and their matches in the 
animal studies were observed. DOSY sequence experiments had almost 
identical results to those of the animal plasma samples. The effect of strong lipid 
signals on the spectra was noticeable and they might have covered other signals 
that could represent a significant biomarker.  
 
Taurine signal had a stronger effect on the study group (carotid and femoral) in 
the CPMG experiment. This was contradicting the findings in the animal models, 
whereas taurine was stronger in the control groups (plasma and solid tissue). 
 
2-oxoglutarate was another signal noticed to be stronger in the control group 
(CPMG experiment), in both animal and human plasma models of this study. 
There has been no clinical research into the specific role of 2-oxoglutarate in 
atherosclerosis, and whether it has a protective function. 
 
Choline was noticed to be present in the human plasma experiment as a stronger 
signal in the control group. Although choline intake was not found to be linked to 
cardiovascular disease, the long-term consumption may have a preventative role 
by reducing inflammation and other risk factors (Rajaie & Esmaillzadeh, 2011). 
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Chapter 6: NMR analysis of plaques 
Human samples 
 
This chapter will describe High Resolution Magic Angle Spinning 1H-NMR 
spectroscopy analysis of sections of plaque samples obtained from 56 patients 
using CPMG and 1D NOESY pulse sequences. Samples were prepared as per 
Section 2.4, 2.4.1 and 2.2.4. Data were collected as explained in Section 2.3.2. 
Spectra processing was done as per Section 2.5. Statistical analysis was done 
as per Section 2.6. 
 
Each plaque section was given two letters followed by a number and a letter for 
identification purpose. The letters were: (Ca) for patients with symptomatic carotid 
disease and (Fe) for patients with symptomatic femoral disease. The number 
given to each sample was according to their order of recruitment. The final letter 
was to echo the letter given to the section during sample preparation. 
 
6.1 Results 
Out of 64 patients recruited for this study, 6 patients (3 carotid – 3 femoral) had 
their operation cancelled, 1 carotid plaque sample was lost in theatre prior to 
collection, and 1 femoral plaque was excluded from the study as sample was too 
fragmented to section and process. Sections from 56 plaque samples were 
analysed. Total number of sections was 173 (111 carotid vs 62 femoral). Patients’ 
demographics, relevant past medical history and current medications are 
summarised in table 16. More detailed statistical analysis of patients’ data will be 
discussed throughout this chapter wherever found relevant. 
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 Carotid Femoral P-value 
Number of patients 40 16 0.0013 
Number of sections 111 62 0.0002 
Male/Female 26/14 13/3 0.0578 0.0124 
Age (years) 
Range 44-91 46-87  
Mean 70.8 ± 10.9 68.9 ± 9.8 0.5594 
Median 73 69  
BMI (kg.m-2) 
Range 20 - 43 16.8 - 39  
Mean 27.5 ± 3.9 26.4 ± 5.7 0.4296 
Median 28.5 26  
Smoke 
Current 14 7  
Ex 18 7  
Never 8 2  
Alcohol (unit) 
Range 0-75 0-65  
Mean 12.6 ± 13.1 19.4 ± 15.3  
Median 10 14.5  
Hypertension 
Treated 23 10  
Untreated 3 1  
Diabetes Mellitus 
Diet 4 0  
Oral 4 0  
Insulin 2 0  
hyperlipidaemia 10 6  
Antiplatelet therapy 36 15  
Statins 36 13  
Table 16: Patients demographics and medical background – NMR plaque study 
 
6.1.1 Analysis of atherosclerotic carotid and femoral plaques – CPMG 
sequence 
 
6.1.1.1 PCA model 
A PCA model was produced for all the spectra obtained from the plaques using 
CPMG sequence. A strong model was demonstrated in this experiment with 16 
components detected. The goodness of fit R2X(cum) was 0.769. The predictive 
ability Q2(cum) was 0.264. The score scatter of this model showed a clear 
separation between the carotid and femoral plaque. Samples Ca-036-E, Ca009-
E and Ca-060-G were outliers with possible effect on the separation in this model 
(figure 62). 
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Figure 62: Score scatter of the PCA model - carotid v femoral plaques - CPMG 
 
Those outliers were excluded and a second PCA model was produced. An 
improved model was demonstrated in with 16 components detected. 
The goodness of fit R2X(cum) was 0.745. The predictive ability Q2(cum) was 
0.341. The score scatter of this model continued to show a clear separation 
between the carotid and femoral plaque (figure 63). 
 
 
Figure 63: Score scatter of the PCA model - carotid v femoral plaques (excluding the 
outliers) - CPMG 
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6.1.1.2 PLS-DA and OPLS-DA models 
After excluding the same outliers (Ca-036-E, Ca009-E and Ca-060-G, a PLS-DA 
model was produced for all the spectra obtained from analysing the plaques using 
CPMG sequence. 4 components were detected in this model.  The goodness of 
fit R2X(cum) was 0.347 and R2Y(cum) was 0.828. The predictive ability Q2(cum) 
was 0.668. A clear separation was observed between the two groups (figure 64).  
 
An OPLS-DA model for this experiment showed similar observations, with no 
additional information to further identify the spectral signals which were 
potentially affecting group separation. 
 
 
Figure 64: Score scatter of the PLS-DA model - carotid v femoral plaques (excluding 
the outliers) - CPMG 
 
The matching loading column plots of these models produced 43 signals 
potentially causing the discrimination between the carotid and femoral groups 
(figure 65). Table 17 summarises the chemical shifts (bins) from strongest to 
weakest that could be responsible for differentiating the groups, and their 
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correlating plasma metabolites responsible for the high scores (95% Confidence 
Intervals)  (Nicholson, et al., 1995). 
 
 
Figure 65: Loading column of the PLS-DA model - carotid v femoral plaques (excluding 
the outliers) – CPMG 
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Carotid plaques Femoral plaques 
Bin 
Signal 
multiplicity 
Molecule Bin 
Signal 
multiplicity 
Molecule 
3.26 t Taurine 1.38 m Lactate 
3.94 dd Tyrosine 1.34 m Lactate 
3.66 m/t 
Choline 
Glutamine 
1.3 m Lactate 
3.9 dd β-glucose 1.42 m Lactate 
3.98 dd Tyrosine 0.98 m Lipid  
3.7 m α-glucose 5.58 none  
3.22 none  5.3 m 
Unsaturated 
lipid 
3.74 m α-glucose 5.42 none  
3.62 m/t 
Choline 
Glutamine 
5.54 none  
3.18 none  5.18 m/d 
Glyceryl of 
lipids 
α-glucose 
3.46 m Proline 5.38 none  
4.02 dd Tyrosine 5.46 none  
4.38 none  5.22 m/d 
Glyceryl of 
lipids 
α-glucose 
4.3 none  5.62 none  
4.34 none  5.26 M 
Unsaturated 
lipid 
1.7 none  5.5 none  
2.86 dd Asparagine 1.26 m Lipid 
2.3 m 
3-
hydroxybutyrate 
5.34 none  
3.42 none  5.66 none  
3.82 m α-glucose 1.18 m Lipid 
3.86 m α-glucose 3.34 none  
3.3 none     
Table 17: Chemical shifts responsible for high scores and correlating metabolites. PLS-
DA - carotid v femoral plaques – CPMG 
(s=singlet, d=doublet, dd=doublet of doublet, t=triplet, q=quartet, m=complex multiplet) 
 
The strongest signal which possibly affected the carotid plaque samples’ 
behaviour in the magnetic field was a triplet at 3.26 ppm. This signal corresponds 
to taurine. Bins in the range 3.94-3.98 with a doublet of doublets signal are 
consistent with tyrosine, which is an amino acid used in protein biosynthesis. This 
was also a dominant signal in the carotid group. In addition, the carotid samples 
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were affected by proline (3.46 ppm - complex multiplet) and asparagine (2.86 
ppm - doublet of doublets). 
 
Some of the signals were overlapping which made it difficult to establish which 
metabolite was causing the shift. Bins in the range 3.62-3.66 ppm have a complex 
multiplet signal are consistent with choline. However, when the area is dominated 
by a triplet signal it echoes glutamine. These bins were stronger in the carotid 
group, although the signals kept altering between the two metabolites 
characteristics, and it was difficult to determine which was causing the stronger 
effect. 
 
The femoral group was predominantly affected by signals in the bins range of 
1.30-1.42 and 5.26-5.30. There was a large lactate signal (complex multiplet) in 
the range 1.30-1.42 which could be the dominant metabolite influencing the 
femoral samples behaviour in the magnetic field. While unsaturated lipid signals 
(complex multiplet) were detected in the range 5.26-5.30, which also had a 
stronger influence on the femoral samples. Further lipid signals (complex 
multiplet) affecting the femoral samples were detected at bins 0.98, 1.26 and 
1.18. 
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6.1.2 Analysis of atherosclerotic carotid and femoral plaques – DOSY 
sequence 
 
6.1.2.1 PCA model 
A PCA model was produced for all the spectra obtained from the plaques using 
DOSY sequence. A strong model was demonstrated in this experiment with 15 
components detected (figure 66). The goodness of fit R2X(cum) was 0.831. The 
predictive ability Q2(cum) was 0.511. The score scatter of this model showed a 
clear separation between the carotid and femoral plaque. Samples Fe-049-E and 
Ca-030-E were outliers with possible effect on the separation in this model (figure 
67). Excluding these outliers though did not affect the model’s strength or 
separation pattern. Those outliers were kept in the experiment and monitored for 
similar behaviour in the subsequent analysis. 
 
 
Figure 66: PCA model – carotid v femoral plaques - DOSY 
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Figure 67: Score scatter of the PCA model - carotid v femoral plaques - DOSY 
 
6.1.2.2 PLS-DA and OPLS-DA models 
A PLS-DA model was produced for all the spectra obtained from analysing the 
plaques using DOSY sequence. 3 components were detected in this model.  
The goodness of fit R2X(cum) was 0.389 and R2Y(cum) was 0.713. The predictive 
ability Q2(cum) was 0.62. A clear separation was observed between the two 
groups (figure 68). From the score scatter, only two samples from the femoral 
group were far from the other clustered samples and somehow placed closer to 
the carotid samples. Those two samples were belonging to the same patient Fe-
055(C+G). On reviewing the medical records, this patient was the only one in the 
femoral endarterectomy group with an established chronic kidney disease. The 
plaque obtained from this patient was described by the surgeon performing the 
endarterectomy as “stenosed throughout with no apparent maximum point”. This 
may explain these samples behaviour in this model. However, a third section of 
this plaque (Fe-055-E) was also analysed in this experiment and it did not behave 
in the same way. Furthermore, excluding Fe-055-C and Fe-055-G or excluding 
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all the samples from patient Fe-055 did not add or affect the strength of the PLS-
DA model (3 components -  R2X(cum) = 0.39 - R2Y(cum) = 0.741 - Q2 = 0.658) 
or the separation observed (figure 69). These samples were kept in the 
experiment and monitored for similar behaviour in the subsequent analysis. 
 
 
Figure 68: Score scatter of the PLS-DA model - carotid v femoral plaques - DOSY 
 
 
Figure 69: Score scatter of the PLS-DA model - carotid v femoral plaques (excluding 
patient Fe-055) - DOSY 
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An OPLS-DA model for this experiment showed similar observations, with no 
additional information to further identify the spectral signals which were 
potentially affecting group separation. 
 
The matching loading column plots of these models produced 49 signals 
potentially causing the discrimination between the carotid and femoral samples 
(figure 70). Tables 18 and 19 summarise the chemical shifts (bins) from strongest 
to weakest that could be responsible for differentiating the groups, and their 
correlating plasma metabolites responsible for the high scores (95% Confidence 
Intervals)  (Nicholson, et al., 1995). 
 
 
Figure 70: Loading column of the PLS-DA model - carotid v femoral plaques - DOSY 
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Carotid plaques 
Bin Signal multiplicity Molecule Bin Signal multiplicity Molecule 
3.12 dd 
Phenylalanine 
Histidine 
0.72 none  
3.84 none  0.56 none  
3.8 q Alanine 2.72 d Aspartate 
0.64 none  4.16 none  
3.56 dd 
Threonine 
α-glucose 
3 none  
2.68 dd Aspartate 0.76 none  
4.2 none  4.24 none  
3.76 q Alanine 3.72 dd α-glucose 
3.08 none  0.52 none  
3.48 dd 
Threonine 
α-glucose 
2.6 none  
3.52 dd 
Threonine 
α-glucose 
3.28 t Taurine 
3.04 none  2.56 none  
0.6 none  4.52 d β-glucose 
0.68 none  3.4 t Taurine 
3.6 d Threonine 2.52 none  
2.64  d aspartate 3.24 t Taurine  
3.16 none     
Table 18: Chemical shifts responsible for high scores and correlating metabolites. PLS-
DA - carotid plaques – DOSY 
 
Femoral plaques 
Bin Signal multiplicity Molecule 
1.52 m Lipid (mainly VLDL) 
1.48 m Lipid (mainly VLDL) 
1.2 d 3-hydroxybutyrate 
2.16 m Glutamine/Glutamate 
1.24 m Lipid (mainly LDL) 
1.16 m 3-hydroxybutyrate 
1.44 m Lipid (mainly VLDL) 
2.12 m Glutamine/Glutamate 
1.28 m Lipid (mainly VLDL) 
1.92 m 
Isoleucine 
Proline 
Lipid 
2.92 dd Asparagine 
2.8 none  
2.96 dd Asparagine 
2.2 m Glutamine/Glutamate 
1.96 m 
Isoleucine 
Proline 
Lipid 
1.56 m Lipid (mainly VLDL) 
Table 19: Chemical shifts responsible for high scores and correlating metabolites. PLS-
DA - femoral plaques – DOSY 
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(s=singlet, d=doublet, dd=doublet of doublet, t=triplet, q=quartet, m=complex multiplet) 
Analysing the table of chemical shifts in this model suggested that some of the 
signals were overlapping which made it difficult to establish which metabolite was 
causing the shift. The carotid endarterectomy group had stronger signals of 
amino acids predominantly. Bins at 3.12 with a doublet of doublets signal can be 
correlating to either phenylalanine or histidine. This was the strongest amino acid 
affecting the carotid group. Bins in the range 3.76-3.80 ppm have a quartet 
spectral signal are consistent with alanine. Bins in the range 3.48-3.60 ppm have 
a doublet of doublets spectral signal are consistent with threonine or α-glucose. 
These signals were stronger in the carotid group and mostly responsible for 
samples behaviour within the magnetic field. 
 
Another amino acid which had stronger signal in the carotid group was aspartate 
(2.64-2.72 ppm - doublet of doublets). Taurine signal (3.24-3.40 - triplet) was also 
stronger in the carotid group, although not as dominant as it was in the CPMG 
sequence experiment (Section 6.1.1.2).  
 
It was noticeable from the table of chemical shifts that lipid metabolites had 
stronger signals in the femoral group, with mainly LDL (low-density lipoprotein) 
and VLDL (very low-density lipoprotein) affecting their behaviour within the 
magnetic field. The other metabolites that were potentially affecting the femoral 
samples were 3-hydroxybutyrate (1.16 ppm - complex multiplet) and amino acids 
such as; glutamine/glutamate (2.12-2.2 ppm - complex multiplet) and asparagine 
(2.92-2.96 ppm - doublet of doublets). Bins in the range 1.92-1.96 ppm have a 
complex multiplet spectral signal were stronger in the femoral group. These are 
consistent with isoleucine, proline or lipid. Due to signals overlapping, it was 
difficult to establish the metabolite which was causing the shift. 
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6.2 Discussion 
In contrast to the animal solid tissue experiment, human solid tissue experiment 
has shown much stronger models and clearer results. This could be purely due 
to the large sample size used in the human experiment. Similarities were also 
observed between the CPMG and DOSY sequence experiments. 
  
The dominant lipid signals affecting the behaviour of femoral samples were 
repeated in both experiments. However, this was not observed in the human 
plasma experiment (carotid v femoral). This raises the issue of identifying solid 
tissue related biomarkers that are not circulating in plasma. This might also 
question the applicability of solid tissue NMR analysis in clinical practice. 
 
The presence of amino acid signals in all the models of this experiment was 
noticed. These were mainly affecting carotid plaques, although it was challenging 
to detect a regular pattern of the individual amino acids. 
 
Perhaps the most notable finding is the possible effect of taurine signals on 
plaques. Taurine signals have been observed in the animal (plasma and solid) 
as well as human plasma models in this study. Although, they have shown a 
much stronger effect on the carotid plaques.  A finding which could be difficult to 
interpret considering the preventative role of taurine on cardiovascular diseases 
(Murakami, 2014). 
 
 
 
 
154 
 
 
Chapter 7: Other experiments 
 
This chapter will describe other experiments carried out as part of this study. 
 
7.1 Urine experiment 
1H-NMR spectroscopy analysis of urine obtained from 81 patients. Samples were 
prepared as per Section 2.2.3 and 2.3.1. Data were collected as explained in 
Section 2.3.2. 
 
Each plasma sample was given a set of letters followed by a number for 
identification purpose. The letters were: (Ca) for patients with symptomatic carotid 
disease, (Fe) for patients with symptomatic femoral disease, and (Ctrl) for 
patients from the control group. The number given to each sample was according 
to their order of recruitment. 
 
7.1.1 Analysis of urine samples – NOESY sequence 
This experiment was run on 25 patients only. During the NMR processing and 
data collection it was noticed that samples were very unstable in the magnetic 
field. The main problem was the effect of this instability on the temperature of the 
NMR experiment. This was widely variable despite many attempts to re-process 
the samples. A large water signal was in all the examined samples which was 
difficult to suppress with D2O. This was also affecting the fids obtained from the 
NMR and creating a lot of noise which ultimately did not allow gaining any valid 
results (figure 71). The concern was that these data would have not been 
obtained using the same methods, despite trying different techniques to control 
the process. 
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It was also not possible to identify the reason behind such a large water signal in 
all the samples. Although there was some variation in time of sample collection, 
and some patients may not have had enough starvation time. 
 
 
Figure 71: NMR spectra of urine sample – NOESY 
 
After discussion with Dr Fisher regarding the problem faced while processing 
urine samples the experiment was discontinued, and urine data were not included 
in this study. 
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7.2 Histopathological experiment 
Solid tissue samples were prepared for histopathological examination as per 
Section 2.2.4. Brachiocephalic artery specimens obtained from mice (6 ApoE-/- 
v 5 control) were included in this experiment.  216 arterial plaque sections (144 
carotid v 72 femoral) obtained from 57 patients were included in this experiment. 
Initial histological examination was carried out on samples from 4 patients (19 
slides), by Dr N West from Leeds Institute of Cancer and Pathology at the 
University of Leeds. 
 
Those specimens had a significant degree of destruction, and Dr West was 
unable to assess them adequately for plaque stability. This could be due to a high 
calcium level in the specimens which affected the sectioning process, or because 
of the effect of formic acid used in the decalcification process.  
 
To gain meaningful histological information from the specimens, a detailed cross 
examination by a second pathologist would have been necessary. Concluding 
this experiment therefore would have been time consuming and may not offer a 
confident histological examination of the specimens. The experiment was 
postponed, and its results will not be included in this study. 
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Chapter 8: Final discussion and conclusions 
 
Identifying plaque instability in asymptomatic carotid disease was the centre of 
this study. 
 
Current recommendations for surgical management of asymptomatic 50-99% 
carotid stenosis are guided by two factors, patient’s fitness for surgical 
intervention and the clinical/imaging features associated with an increased risk of 
late stroke. 
 
The imaging features which are specific to the plaque morphology include 
stenosis progression, large plaque area, large juxta-luminal black area on CT, 
plaque echolucency and intra-plaque haemorrhage on MRI (Naylor, et al., 2017). 
Despite the advances in imaging modalities and their ability to detect some 
features of plaque instability, full understanding of the pathophysiology of plaque 
instability will allow early intervention in patients with high risk of developing 
stroke from the unstable plaque. 
 
To date, no serum or urine marker has been shown to predict plaque instability 
and the risk of future cerebrovascular events. 
 
The work in this thesis has compared metabolic profiles of plasma and plaques 
from patients with symptomatic carotid stenosis undergoing endarterectomy, 
plasma and plaques from patients with symptomatic femoral stenosis, and 
plasma from patients without carotid or femoral disease (control). 
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We also compared plasma and solid tissues from mammalian model (mice), and 
further compared them to the human experiment. 
 
This was carried out using nuclear magnetic resonance (NMR) spectroscopy to 
analyse the metabolic profiles of plasma and plaques, and potentially identifying 
predictive biomarkers of plaque instability.  
 
8.1 NMR plasma experiments 
Investigating the ability to analyse metabolic profiling in plasma using NMR 
spectroscopy has increased significantly in recent years. NMR studies have been 
focussed on coronary artery disease in general, although carotid related studies 
have been carried out by many researchers as explained in chapter 1.  
 
Animal plasma experiments in this study have shown weak models and could not 
produce significant results that could confidently establish certain metabolites as 
atherosclerotic biomarkers. Sample size was certainly an important factor in this 
conclusion. A separate experiment was carried out alongside this study, adding 
data from this study to data obtained with the same methodology by A Bekhit 
from the University of Leeds, School of Medicine, from a different group of ApoE-
/- and control mice (n=12). This experiment allowed the production of stronger 
models, and suggested that larger sample size perhaps would have created more 
reliable results. 
 
The human plasma (carotid, femoral and control) experiments in this study as 
well could not confidently establish certain metabolites as atherosclerotic 
biomarkers. The effect of strong lipid signals on the spectra was noticeable and 
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they might have covered other signals that could represent a significant 
biomarker. However, similarities were observed between the animal and human 
models, and 3 metabolites (2-oxoglutarate, choline and taurine) were identified 
as potential biomarkers. Although there have been many studies on amino acids 
role in atherosclerosis development, no clinical research considered the specific 
role of 2-oxoglutarate and whether it has a protective function, considering its 
strong effect on the control subjects in both the animal and human plasma 
experiments.  
 
Taurine is thought to play an important role in supressing the development of 
atherosclerosis and has preventative influence on cardiovascular diseases 
(Murakami, 2014). There have been recent NMR based studies on the effect of 
taurine on dyslipidaemia in mammalian models (Kim & Bang, 2017), but no 
similar studies investigated the effect of taurine on carotid disease. In our study 
taurine signals were more evident in the control group in the animal experiment. 
 
Choline was noticed to be present in the human plasma experiment as a stronger 
signal in the control group. Choline effect on cardiovascular disease has always 
been controversial. Earlier studies advocated a preventative role, while more 
recent studies suggested that choline plasma metabolites are associated with a 
higher risk of cardiovascular disease (Guasch-Ferré, et al., 2017). Future 
research study may further explain the potential role of choline in carotid disease 
and plaque instability. 
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8.2 NMR solid tissue experiments 
With the advances in technology, NMR based analysis of solid tissues has been 
increasingly investigated in recent years, although no studies tried to address the 
subject of this thesis. However, researchers have used the extracts of solid 
tissues in NMR based experiments, with no successful identification of a reliable 
biomarker of plaque instability. 
 
The use of high-resolution magic angle spinning NMR spectroscopy to analyse 
the metabolic profiles of intact plaques is a novel approach. 
 
Similar to the plasma experiments, animal solid tissue experiments in this study 
have shown weak models and could not produce significant results that could 
confidently establish certain metabolites as atherosclerotic biomarkers. Sample 
size was an important factor in this conclusion. 
 
In contrary, human solid tissue experiments (CPMG and DOSY sequences) have 
shown much stronger models and clearer results. Spectra gained from these 
experiments were the first to be described, with no comparable studies in the 
literature. Metabolic profiles of plaques obtained from patients undergoing carotid 
and femoral endarterectomy were analysed in detail. The dominant lipid signals 
affecting the behaviour of femoral plaques were observed in all models. While the 
mixed presence of amino acid signals in all the models of this experiment was 
also noticed. These were mainly affecting carotid plaques, although it was 
challenging to detect a regular pattern and draw conclusions regarding the 
individual amino acids. 
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Perhaps the most notable finding is the possible effect of taurine on carotid 
plaques. Taurine signals have been observed in the animal (plasma and solid) 
as well as human plasma models in this study. Although, they were merely 
affecting the control groups. Taurine’s strong influence on the metabolic profiling 
of carotid plaques raises the possibility of a potential biomarker of plaque 
instability.  
 
In this study the maximum stenotic point was determined according to the 
surgeon’s impression, which is essentially a subjective assessment. In addition, 
maximum stenosis point may not necessary reflect plaque instability. Spectra 
from plaque sections were treated collectively in this study, which allowed a direct 
comparison between carotid and femoral plaques. Spectra from individual 
sections were not further analysed. This is mainly due to the lack of information 
regarding stability/instability of each section, and therefore plaque. 
 
Due to current clinical practice it was not feasible to obtain plaques from patients 
with asymptomatic carotid disease. A histological assessment of the plaques in 
this study would have added extra valuable information for further analysis. 
 
Furthermore, histological assessment of the brachiocephalic samples from the 
mice used in this experiment will confirm the validity of the model, and may 
improve the weak findings of the animal experiment. 
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8.3 Future research 
Further work is required regarding the histological examination of plaque 
sections. An objective assessment of the plaque instability will improve the study 
outcome and add a different aspect to the current results. 
 
Moreover, being able to identify the stable sections from each plaque will allow a 
more detailed analysis of NMR spectra of these sections. This may further explain 
the findings of this study, and will help in developing future NMR based studies 
on the effect of taurine on atherosclerosis and plaque instability. 
 
It will also be worth running a new experiment on the urine samples obtained 
during this study. Stronger NMR devices (>500 MHz) have been used in other 
NMR based urine studies. Following a stricter morning sample collection might 
make urine samples more concentrated and therefore have less water. This could 
tackle the problem with urine samples faced in this study. 
 
Finally, a larger sample size mammalian study may produce stronger models and 
more specific results. This could be more directed towards certain metabolites 
detected in this study, especially amino acid pathways and their effect on plaque 
instability. 
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